

# **Safety of praziquantel in persons with and without schistosomiasis: systematic review and meta-analysis**

Anthony Danso-Appiah<sup>1,2,\*</sup>, David Owiredu<sup>2</sup>, Morrison Asiamah<sup>2</sup>, Kwadwo Akuffo<sup>3</sup>, Paolo Eusebi<sup>4</sup>, Guo Jiangang<sup>5</sup>, Pauline Mwinzi<sup>6</sup>, Daniel G. Colley<sup>7</sup>, Paul Hagan<sup>8</sup>, M. Hassan Murad<sup>9</sup>, Amadou Garba Djirmay<sup>5</sup>

<sup>1</sup>UG Centre for Evidence Synthesis and Policy (UGCESP), School of Public Health, P. O. Box LG13, Legon, Accra, Ghana

<sup>2</sup>Department of Epidemiology and Disease Control, School of Public Health, University of Ghana, Legon, Accra, Ghana

<sup>3</sup>Kwame Nkrumah University of Science and Technology, Kumasi, Ghana

<sup>4</sup>Health Planning Service, Regional Health Authority of Umbria, Italy <sup>4</sup>Department of Medicine, University of California, San Francisco, United States

<sup>5</sup>WHO Department of Control of Neglected Tropical Diseases, Geneva, Switzerland

<sup>6</sup>Expanded Special Project for Elimination of Neglected Tropical Diseases (ESPEN), WHO Regional Office for Africa Brazzaville, Congo

<sup>7</sup>Center for Tropical and Emerging Global Diseases, University of Georgia, Room 330B - Coverdell Center, 500 D.W. Brooks Drive -30602 - Athens Georgia, United States

<sup>8</sup> Faculty of Health Sciences, University of Hull, Hull, UK

<sup>9</sup>The Kern Center for the Science of Healthcare Delivery, Mayo Clinic, Rochester, Minnesota, USA

\* Correspondence: Anthony Danso-Appiah  
[adanso-appiah@ug.edu.gh](mailto:adanso-appiah@ug.edu.gh); [tdappiah@yahoo.co.uk](mailto:tdappiah@yahoo.co.uk)

## **ABSTRACT**

Millions of praziquantel doses have been delivered in schistosomiasis endemic populations through preventive chemotherapy. However, no comprehensive assessment of short and long-term safety has been conducted. This systematic review assessed safety of praziquantel in persons with and without schistosome infections who received praziquantel treatment.

## **Methods**

We identified relevant studies (published, unpublished, in press or preprint) that assessed safety of praziquantel without language restriction. We searched MEDLINE, EMBASE, CINAHL, and LILACS from 1978 to 31<sup>st</sup> October 2021, using well-formulated and piloted search strategy. We also searched the Cochrane Infectious Diseases Group Specialized Register, CENTRAL (The Cochrane Library 2021), mRCT, Google Scholar, Hinari and Africa Journals Online. References of relevant studies were checked and experts were contacted for additional studies. One author searched and managed the search output. Two authors selected studies, extracted data and assessed quality of the included studies for risk of bias. Activities at all stages were checked independently by a third reviewer. Discrepancies were resolved through discussion among the authors. Data were analysed with RevMan v5.4 and STATA v17. Binary outcomes were reported as risk ratio using random-effects model and continuous outcomes as mean difference, all presented with their 95% confidence intervals. P-value was set at 0.05. Heterogeneity was assessed using  $I^2$ -static and where possible sensitivity analysis was conducted. When pooling of data was not possible, we presented data in a narrative synthesis and as tables.

## **Main results**

The search retrieved 3202 studies of which 134 met the inclusion criteria; 94 (70.1%) were conducted in Africa, 17 (12.7%) in Asia, 15 (11.2%) in the Americas (14 from Brazil), 4 (3.0%) in the Middle East and 3 (2.2%) in Europe. Praziquantel mostly resulted in mild-to-moderate and transient adverse events, however, majority of the included studies had design issues, including very short follow-up times (mostly few hours) for assessing incidence of adverse events. Less than <10% of the studies reported severe or serious adverse events. The subgroup analyses of twenty studies comparing school age children (SAC) and adults, and involved over one million participants found no difference in the nature of adverse events, but SAC experienced higher incidence than adults: headache (RR 3.07, 95% CI 2.32 to 4.06, twenty studies,  $I^2 = 98%$ ,  $p < 0.00001$ ), dizziness (RR 1.80, 95% CI 1.36 to 2.37,  $p = 0.0001$ ), vomiting (RR 2.43, 95% CI 1.87

to 3.14,  $I^2 = 98\%$ ;  $p < 0.00001$ ), four time for abdominal pain (RR 3.97, 95% CI 3.09 to 5.10,  $I^2 = 96\%$ ,  $p < 0.00001$ ), nausea (RR 1.67, 95% CI 1.32 to 2.12,  $I^2 = 97\%$ ,  $p < 0.0001$ ), general discomfort (RR 1.32, 95% CI 1.03 to 1.68,  $I^2 = 97\%$ ,  $p < 0.00001$ ), fever (RR 4.78, 95% CI 3.04 to 7.52,  $I^2 = 98\%$ ,  $p < 0.00001$ ), diarrhoea (RR 1.41, 95% CI 1.12 to 1.78,  $I^2 = 92\%$ ,  $p < 0.00001$ ), itching (RR 2.42, 95% CI 1.58 to 3.70,  $I^2 = 93\%$ ,  $p < 0.0001$ ) and breathing difficulty (RR 2.46, 95% CI 1.41 to 4.29,  $I^2 = 92\%$ ,  $p = 0.002$ ). There was no statistically significant difference in incidence of swelling. Some of the studies that assessed safety in pregnant women reported serious events including miscarriages, foetal deaths and congenital anomalies, but the evidence is inconclusive given the limited numbers. Some studies reported praziquantel-related visual adverse events, but evidence is limited and remains inconclusive. There was paucity of data on long term adverse events, and events in co-morbidity, polypharmacy, co-infection with taeniasis. Generally, adverse events research in this area lacked methodological rigour.

## Conclusions

The evidence generated from this review involving millions of people and millions of doses from different geographic locations with mostly mild-to-moderate and transient adverse events shows praziquantel is safe. However, given that the primary studies included in the review had design issues, including over 95% assessing adverse events over very short follow-up times, means serious long-term adverse events would have been missed. Also, the fact that some pregnant women who received praziquantel experienced serious events including miscarriages, foetal deaths and congenital anomalies calls for caution in the inclusion of pregnant women, particularly in their first trimester, in preventive chemotherapy campaigns. Additionally, the studies that reported severe visual adverse events raise safety concerns. Praziquantel is now offered repeatedly in endemic communities and the fact that in some settings up to 90% of those without infection could be offered the drug and the fact that there was no study that compared safety between infected and non-infected recipients, warrants further research. Evidence on safety in pregnant women and their foetuses, co-morbidity, polypharmacy, co-infection with taeniasis, as well as co-administration with drugs used in other preventive chemotherapy programmes, remain inconclusive and further research with long follow-up that should include blood chemistry analysis to provide additional evidence on long term safety, is warranted. This systematic review has exposed the lack of methodological rigour in adverse events studies and recommends future research should use robust and standardized design, methods, conduct and reporting.

**Key words:** Praziquantel, safety, adverse events, preventive chemotherapy, women of reproductive age, school age children, adults

## **Background**

Schistosomiasis is caused by the blood fluke, a group of flat worms that reside in the blood vessels in the human hosts and presents as an acute, but mostly chronic illness (WHO 2002). It has been estimated that around 800 million people are at risk of the infection worldwide and over 250 million may be infected (Steinmann et al. 2006, King et al. 2015, WHO 2021, WHO 2022). In 2018, it was estimated that over 230 million infected people required preventive chemotherapy (PC) worldwide (Lo et al. 2018; WHO 2021). Groups at risk for schistosomiasis are preschool-aged children (PSAC), school-aged children (SAC), adults in certain occupational groups such as farmers who rely on water bodies and irrigations for their work, women who are in contact with infected water sources for domestic activities, and entire communities in high-risk areas (WHO 2021). Around 90% of the burden of the disease is concentrated in Sub Saharan Africa (SSA) (WHO 2022).

Preventive chemotherapy (PC), started in the early 2000s as the control strategy recommended by the WHO, is applied in most endemic countries (WHO 2002, WHO 2006, WHO 2012, WHO 2013, WHO 2021). Within the PC concept, endemic countries are urged to embark on mass drug administration (MDA) with praziquantel (PZQ) at a single 40 mg/kg oral dose using infection prevalence thresholds. Several drugs have been used or tried in treating schistosomiasis and later abandoned because of adverse events or poor effect (Cioli 1995, more references). There is no effective antischistosomal vaccine as yet (Gryseels 2000; Fenwick 2006a; McManus 2008; Colley and Secor 2014; Fonseca et al. 2015) and control will continue to rely on praziquantel, a broad spectrum antischistosomal drug introduced on to the market in the early 1980s, with no real alternative. The common adverse effects reported across studies are abdominal pain, nausea, vomiting and diarrhoea, which are usually mild-to-moderate and transient, lasting less than 24 hours.

The neglected tropical disease (NTD) earlier road map and the London Declaration of NTD moved partners to pledge commitment towards supporting the fight against schistosomiasis to reach a target of 75-100% coverage of school-aged children living in endemic regions by 2020, and to eliminate the disease in some regions (reference). The support led to increased donation of PZQ to reach excesses of 250 million tablets per year to take care of the 100 million people that

needed treatments. The most recent data estimated the number of people that required PZQ for schistosomiasis globally in 2020 at 241.3 million across 51 countries (133.3 million SAC and 108 million adults), an increase over that in 2019 (235.4 million) in 2019 (WHO 2021). Africa remains the highest burden of schistosomiasis (>90% of the people who require PC for schistosomiasis) according to the latest mapping estimate (WHO 2018, WHO 2020, WHO 2021). In January 2021, WHO launched a new road map to guide action against NTDs and to set the targets achievable for all NTDs by 2030 (WHO 2021). The targets for 2030 are elimination of schistosomiasis and STH as public health problems in all endemic countries and interruption of schistosome transmission in humans in selected countries (WHO 2021).

In the PC strategy, WHO recommends PZQ treatment of all persons in endemic communities with infection levels reaching 10% threshold whether infected or without infection (Danso-Appiah et al. 2022; WHO 2021). Treating individuals without infection (that could reach up to 90% of the village's population) has moral and ethical implications for public health. Additionally, the recommendation to treat pregnant and lactating women, for example, lacks strong evidence (WHO 2022). Also, in people coinfecting with other infections such as taeniasis, or with mixed infections with the different types of schistosomiasis in the same individual, with co-morbidities, or the very young children and infants, the evidence is weak and inconclusive (WHO 2022). Meanwhile, the donation and use of PZQ will continue to increase and there is urgent need to comprehensively assess the overall safety profile of PZQ, particularly its long-term safety profile as this has not been investigated at all or less sufficiently.

The WHO commissioned this systematic review and meta-analysis in 2018 to comprehensively assess both the short- and long- term safety profile of PZQ from comparative and non-comparative studies across schistosomiasis endemic settings that reported adverse events. Specifically, we assessed adverse events of PZQ by dose (40, 50, 60, 70 mg and 80 mg/kg), and when drugs are co-administered with PZQ e.g. Albendazole, Mebendazole, Pyrantel pamoate or Levamisole (for soil-transmitted helminthiasis), or Albendazole plus either Ivermectin or Diethylcarbamazine [DEC] (for lymphatic filariasis) or ACTs (for malaria). Adverse events were quantified, where possible, and classified based on severity (as mild, moderate, severe or very severe) and reporting any occurrence of serious adverse events (SAEs, i.e. fatal events, life-threatening, requiring hospitalization, requiring discontinuation of treatment, or resulting in disability or incapacity).

## **REVIEW METHODS**

The review was conducted as part of WHO first evidence-based guideline that provided the baseline evidence on which the guideline recommendations were based. Various stakeholders were involved in formulating the review question and the inclusion/exclusion criteria. The review follows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Statement (Page et al. 2020) and Meta-analysis of Observational studies in Epidemiology (MOOSE) (Stroup et al. 2000). The review protocol was registered in the International Prospective Register of Systematic Reviews (PROSPERO) with the ID (CRD42018085695).

### **Criteria for considering studies for this review**

#### ***Types of studies***

Published and unpublished comparative and non-comparative studies that investigated AEs of PZQ treatment.

#### ***Types of participants***

Whole communities or subgroups (preschool age children, school age children, adults including pregnant and lactating women) living in an endemic area and infected with any of the following schistosome species *S. mansoni*, *S. haematobium*, *S. japonicum*, *S. intercalatum* and *S. mekongi* or non-infected, who received PZQ treatment at a single dose of 40 mg/kg or a higher dose (50, 60, 70, or 80 mg/kg).

#### ***Intervention***

1. PZQ at a single oral dose (40 mg/kg)

#### ***Control***

1. Placebo.
2. PZQ divided or higher doses (50, 60, 70, or 80 mg/kg).
3. Medicines co-administered with PZQ such as albendazole, mebendazole, pyrantel pamoate or levamisole (for soil-transmitted helminthiasis), or albendazole plus either ivermectin or

diethylcarbamazine [DEC] (for lymphatic filariasis), ACTs (for malaria), or Azithromycin (Zithromax) for trachoma.

4. No treatment.

### **Outcomes**

#### *Primary adverse events*

- Serious clinical adverse events.
- Serious maternal and foetal events.
- Long term adverse events including tissue organ pathology.

#### *Secondary adverse events*

- All non-serious adverse events.
- Non-serious maternal and foetal events.

### **Adverse Events and related terms defined**

**Adverse Event (AE)** or Adverse Experience is any untoward medical occurrence in a patient or clinical investigation subject administered pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. This is different from **Adverse Drug Reaction (ADR)** which represents all noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reaction. **Unexpected Adverse Drug Reaction (UADR)** is an adverse reaction, the nature or severity of which is not consistent with the applicable product information (e.g., IB for an unapproved investigational medicinal product). **Serious adverse event (SAE)** or experience or reaction encompasses any untoward medical occurrence that at any dose 1) results in death, is life-threatening (an event in which the patient was at risk of death at the time of the event; not an event which hypothetically might have caused death if it were more severe), or requires inpatient hospitalization or prolongation of existing hospitalization or results in persistent or significant disability/incapacity or a congenital anomaly/birth defect.

### **Search strategy for identification of studies**

We identified all relevant studies without language restrictions or publication status (published, unpublished, in press, and ongoing). We searched MEDLINE, EMBASE and LILACS from 1978 to 31<sup>st</sup> October 2021, with no language restrictions. Praziquantel was first tried in humans around

1978 and was introduced onto the market around 1979/1980, hence the date restriction. Search strategies were developed using the major concepts: Praziquantel (all brands), preventive chemotherapy, adverse events, adverse drug reactions, side effects, tolerance and schistosomiasis (including the five types infecting humans - *S. mansoni*, *S. haematobium*, *S. japonicum*, *S. intercalatum* and *S. mekongi*). We also searched the Cochrane Infectious Diseases Group Specialized Register, CENTRAL (The Cochrane Library 2021), mRCT, Hinari, Google Scholar, WHO Library Database and Africa Journals Online. The reference lists of articles were reviewed, and experts in the field of schistosomiasis were contacted for additional or unpublished studies. The results of the database searches were stored and de-duplicated in EndNote X9 library and exported to Rayyan for study selection.

### **Study selection**

Two reviewers screened the results of the search output to identify studies meeting the pre-specified inclusion criteria using a pre-tested study selection flow chart [see Additional file 1]. We included all primary studies (RCTs, quasi-experimental studies, cohort, cross-sectional, case series and case studies). We excluded reviews, opinions or commentaries. Screening was conducted in two stages using the review management software Rayyan (Ouzzani et al. 2016). The first stage screening focused on the titles and abstracts and the second on full texts. Full texts of all potentially relevant studies were retrieved and assessed in detail for inclusion. A screening guide was used to ensure that independent reviewers applied the selection criteria reliably. For authors whose full-text documents were not available via the various internet-based sources, we attempted to contact them directly through the corresponding author's address. If information required to make the decision for inclusion was not obtained, the article was excluded from the analysis. Discrepancies were resolved through discussion between the reviewers.

### **Data extraction and management**

Two reviewers extracted data using a pre-tested data extraction form. Study characteristics such as the country and year in which the study was conducted, the study design and the methods; information on adverse events such as clinical, biochemical or pathological events, and severity and duration; and epidemiological and demographic data – e.g., endemicity status, region where the study was conducted, participants' prior treatment status, target population, sex, age and number of participants, were extracted. When necessary, we contacted the authors of the

published articles on included studies to see if they could clarify or supplement the published results or provide raw data that we could use. In case of multinational studies, we separated the results by country. However, where it was not possible to separate the data by country, the aggregated data was presented and the countries in which the study was conducted were shown. When two or more articles were published from the same study, we selected the study with most data as the parent study and linked the rest. Data were managed with Excel and transported to RevMan for analysis. Discrepancies were resolved through discussion between the reviewers.

### **Assessment of methodological quality**

One reviewer assessed the risk of bias of each trial using The Cochrane Collaboration's risk of bias tool for RCTs (Higgins et al. 2021) and the assessment results was verified independently by another reviewer. Where information in the trial report was unclear, we contacted the trial authors for clarification. We assessed the risk of bias for six domains: sequence generation, allocation concealment, blinding (investigators, outcome assessors and participants), incomplete outcome data, selective outcome reporting and other sources of bias. For each domain, we made a judgment of 'low risk' of bias, 'high risk' of bias or 'unclear' risk of bias. ROBINS-I (Risk Of Bias In Non-randomised Studies - of Interventions), was used to evaluate risk of bias in estimates of the comparative harm or benefit of interventions from studies that did not use randomisation to allocate units (individuals or clusters of individuals) to comparison groups (Sterne et al. 2021). Seven domains through which bias might be introduced into a NRSI was considered. The first two domains, covering confounding and selection of participants into the study, address issues before the start of the interventions that were compared ("baseline"). The third domain addressed classification of the interventions themselves. The other four domains addressed issues after the start of interventions: biases due to deviations from intended interventions, missing data, measurement of outcomes, and selection of the reported result. The STROBE checklist was used to evaluate the reporting methodology in each observational comparative study (Von Elm et al. 2007). Risk of bias and quality results was presented in a table. The Risk of Bias Tool for Prevalence Studies (Hoy et al. 2012) was used to assess the methodological quality and risk of bias for each prevalence study. We resolved any discrepancies by discussion between the authors.

### **Data synthesis**

The absolute rates of adverse events were calculated from all studies and relative risks from comparative trials. Data were analysed and presented as risk ratio (for dichotomous outcomes) or mean difference (for continuous outcomes) with their 95% confidence intervals (CIs). The meta-analyses were performed using Review Manager (RevMan) (<https://training.cochrane.org/online-learning/core-software-cochrane-reviews>). We assessed heterogeneity by inspecting the forest plots for overlapping CIs and outlying data, using the  $I^2$  statistic. When heterogeneity was detected, we used random-effects meta-analysis approach; otherwise, a fixed-effect approach was adopted. We tabulated adverse events and data that could not be meta-analysed. We carried out subgroup analyses to explore potential causes by stratifying the analyses by age – categorized as preschool children (PSAC), SAC or adults – background endemicity by type of schistosome species investigated– categorized as low, moderate and high (for *S. mansoni*, *S. japonicum*, *S. mekongi* and *S. intercalatum*), or low and high (for *S. haematobium*). We conducted a subsidiary, non-randomized comparison of AEs in children with AEs and adults for the same dose (mg/kg) to explore issues around dose applicability in children.

### **Heterogeneity assessment**

We assessed heterogeneity by inspecting the forest plots for overlapping confidence intervals and outlying data using the  $\text{Chi}^2$  test with a P value < 0.1 to indicate statistically significant heterogeneity; and using the  $I^2$  statistic. Although a P-value below 0.05 is generally considered to indicate statistical significance, we used a more sensitive threshold (DerSimonian and Laird 1986; Bossuyt et al. 2013) – i.e. a P-value below 0.10 – to indicate statistically significant heterogeneity. Where such significant heterogeneity is detected, we carried out subgroup analyses based on clinical and methodological differences. For data that could not be pooled quantitatively and where heterogeneity existed between studies, we grouped studies based on similarities.


### **Summary of findings and grading the evidence**

We used GRADE (Alonso-Coello et al. 2016; Santesso et al. 2020) to grade the evidence by looking at 5 main factors that might decrease quality of evidence, 1) study limitations, 2) inconsistency of results, 3) indirectness of evidence, 4) imprecision, and 5) publication bias. We also looked at factors that might increase quality of evidence including, 1) large magnitude of effect, 2) plausible confounding, which would reduce a demonstrated effect, and 3) dose-response gradient (<http://www.gradeworkinggroup.org/>).

## Results

### Description of studies

The search retrieved 3202 studies; 3047 studies from electronic databases and 155 studies from other sources including grey literature and contacts with experts. Seventy-three (73) studies were excluded because of duplication and 2931 were not relevant to the topic. A total of 198 full text studies were obtained of which 134 met the pre-specified eligibility criteria (Fig 1).



**Fig 1** Flow diagram of studies retrieved from relevant electronic databases and other sources.

Sm=*S. mansoni*, Sh=*S. haematobium*, Sj=*S. japonicum*, Smek=*S. mekongi*, Si=*S. intercalatum*, Ts=*Taenia solium*. Five studies did not report the species investigated.

Ninety-four of the 134 studies (70.1%) were conducted in Africa; 17 studies (12.7%) in Asia of which eight were conducted in Philippines (Belizario et al. 2007; Olds et al. 1999c; Olliaro et al. 2011c; Olveda et al. 2016; Santos et al. 1979; Santos et al. 1984; Watt 1986; Watt et al. 1988), seven in China (Fu-Yuan et al. 1984; Hou et al. 2008; Minggang et al. 1983; Minggang et al. 1985; Ming-he 1991; Olds et al. 1999a; Qian 2016), one in Japan (Ishizaki 1979) and one in Thailand (Na-bangchang et al. 2006); 15 studies (11.2%) were conducted in the Americas, 14 in Brazil (Branchini et al. 1982; Carvalho et al. 1984; Coutinho et al. 1983; Da Cunha et al. 1987; da Cunha and Pedrosa 1986; da Silva et al. 1981; da Silva et al. 1986; de Quieroz et al. 2010; Ferrari et al. 2003; Katz et al. 1979; Katz et al. 1981; Katz et al. 1982; Katz et al. 1983; Olliaro et al. 2011a) and one in the USA (Nash et al. 1982); four studies (3.0%) in the Middle East, two in Saudi Arabia (Al-Aska et al. 1990; Azher et al. 1990), one in Israel (Cherit et al. 2014) and one in Yemen (Groning et al. 1985); and three studies (2.2%) in Europe, one each France, Germany and Spain (Bagheri et al 2004; Leopold et al. 1978; Bada et al. 1988) (Table 1).

Olds et al. 1999 conducted a multi-country trial involving China (*S. japonicum*), Kenya (*S. manoni* and *S. haematobium*) and the Philippines (*S. japonicum*) which we included as separate studies (Olds et al. 1999a, Olds et al. 1999b, Olds et al. 1999c). The study by Olliaro et al. 2011 was a multi-country trial conducted in Brazil (*S. mansoni*), Mauritania (*S. manoni* and *S. haematobium*), Philippines (*S. japonicum*) and Tanzania (*S. manoni* and *S. haematobium*). We included data from each country as a separate study (Olliaro et al. 2011a, Olliaro et al. 2011b, Olliaro et al. 2011c, Olliaro et al. 2011d). For the country-wide MDA delivered across 20 districts of several villages, we included data from each district in the meta-analysis as a separate study (Niger MDA 1; Niger MDA 2; Niger MDA 3; Niger MDA 4; Niger MDA 5; Niger MDA 6; Niger MDA 7; Niger MDA 8; Niger MDA 9; Niger MDA 10; Niger MDA 11; Niger MDA 12; Niger MDA 13; Niger MDA 14; Niger MDA 15; Niger MDA 16; Niger MDA 17; Niger MDA 18; Niger MDA 19; Niger MDA 20).

Of the 134 studies, 71 (53.0%) were described by the authors as RCTs, 37 studies (27.6%) were non-randomized clinical trials, 21 (15.7%) were MDA and one case series (Cherit et al. 2014) and one case study (Bada et al. 1988). The design of three studies (Ahmed et al. 1988; Braae et

al. 2016; Ramiandrasoa et al. 2020) was not stated by the authors but data were extracted and reported as unclear study design. Twenty-four (24) of the RCTs had multiple arms, and we analyzed according to arms in order to preserve the randomization code. In some of the non-randomized trials included in this systematic review and meta-analysis, study populations were grouped according to criteria specified by the primary investigators, for example, by intensity of infection, adverse events etc. De Clercq et al. 2002 assessed the efficacy of artesunate (an antimalarial drug) in treating *S. haematobium* and PZQ; we extracted data from the PZQ arm.

*Schistosoma mansoni* was the common schistosome species investigated followed by *S. haematobium* and *S. japonicum* in that order. Fifty-four of the studies were conducted in *S. mansoni* endemic settings and investigated adverse events associated with PZQ for treating for *S. mansoni* infection alone, 37 studies conducted in *S. haematobium* settings investigated adverse events associated with PZQ treatment for only *S. haematobium*, 21 studies involved both *S. mansoni* and *S. haematobium* infections, 15 studies investigated incidence of AEs events with *S. japonicum* alone, two studies investigated assess events in all five schistosome spp. commonly infecting humans (*S. mansoni*, *S. haematobium*, *S. japonicum*, *S. intercalatum* and *S. mekongi*), no study assessed *S. intercalatum* or *S. mekongi* alone and two studies assessed event rates in Taeniasis. No study assessed incidence of adverse events between those with and without schistosome infection receiving PZQ.

Twenty studies (14.9%) compared events rate between SAC and adults and 11 studies assessed mixed infection with *S. mansoni* and *S. haematobium*. Eight studies, four RCTs (Bustindy et al. .2020; Twenonyere et al. 2009; Elliot et al. 2007; Olveda et al. 2016) and four nonRCTs (Chetrit et al. 2014; Adam et al. 2004; Adam et al. 2005; Qian et al. 2016) investigated PZQ administration in pregnant women and five studies (Anto et al., 2011; Sissoko et al., 2009; Fuyuan et al., 1984; Leopold et al., 1978; Rezende, 1985) focused on PZQ-related visual AES. Twenty-seven studies (20.1%) used dose schedules higher than 40 mg/kg and eight studies did not report the dose used. The rest of the studies used 40 mg/kg of PZQ either as a single dose or divided doses. With regard to follow up after treatment, only three studies (2.2%) collected AEs events data one year or more, the rest assessed incidence of events few hours, days or weeks after treatment. One hundred and thirteen studies administered PZQ alone (84.3%), and the common drugs co-administered with PZQ were Mebendazole, Albendazole, Ivermectin and the

Artemisinin compounds (ACTs). All the included studies reported an element of safety (AEs) following treatment with PZQ.

**Table 1** Characteristics of the studies included in the systematic review and meta-analysis

#	Study	Study design	Country	Schistosomiasis type	Outcomes assessed	Diagnostic criteria	Baseline intensity of infection	Baseline prevalence (%)	Treatment (brand)	PZQ dose (mg/kg)	Follow-up	Age category
1	Adam et al. 2004	nRCT	Sudan	Sm	1. Hepatic morbidity	NR	NR	50	PZQ (Distocide)		5 years	Neonates Mothers
2	Adam et al. 2005	nRCT	Sudan	Sm	2. Birth Outcome 3. Birth Weight 4. Adverse events	Stool smear	NR	NR	PZQ	40	1 year postpartum	Neonates Mothers
3	Adoubryn et al. 2012	RCT	Cote d'Ivoire	Sm	1. Adverse Events 2. Cure Rate 3. Egg Reduction Rate 4. Tolerance	Kato-Katz	N/A	0.355	PZQ	40	24 hours	SAC
4	Ahmed et al. 1988	NR	Egypt	Sm+Sh		Kato-Katz	??	NR	PZQ	40	NR	SAC/ADULT
5	Amin et al. 2012	RCT	Sudan	Sm+Sh	1. Adverse Events 2. Cure Rate 3. Egg Reduction Rate 4. Tolerance 5. Acceptability	Kato-Katz 10mL Urine filtration	??	31.1	PZQ	40	24 hours and 7 days	PSAC
6	Al-Aska et al. 1990	RCT	Saudi Arabia	Sm+Sh	1. Adverse events 2. Failure rate	Kato-Katz Urine filtration	Sm=60 EPG Sh=75 eggs /10mL	NR	PZQ	40	24 weeks	SAC/ADULT
7	Anto et al. 2011	RCT	Ghana	Sm+Sh	3. Side effects	Kato-Katz Urine filtration	Sm=53 EPG Sh=12 eggs/10mL	26.7 0.6	PZQ + IVM + ALB	Dose pole *	12 weeks	SAC
8	Asfaw et al. 1988	nRCT	Ethiopia	Sh	Side effects	Urine filtration	5– 235 egg/10mL	NR	PZQ	40	3 days	SAC/ADULT
9	Ayoub et al. 2009	RCT	Sudan	Sm	1. Safety 2. Efficacy	Kato-Katz	N/A	0.16	PZQ	40	28 days	SAC
10	Azher et al. 1990	nRCT	Saudi Arabia	Sm	Side effects	Kato-Katz	NR	NR	PZQ	1.8g**	N/A	ADULT
11	Bada et al. 1988	Case study	Spain	Sm	Side effects	Serology & Stool examination	NR	N/A	PZQ	40 (20x2)	N/A	ADULT
12	Bagheri et al 2004	nRCT	France	NR	NR	NR	NR	NR	PZQ	NR	NR	ADULT
13	Barda et al. 2016	RCT	Cote d'Ivoire	Sm+Sh	1. Adverse events 2. Cure rate 3. Egg reduction rate	Kato-Katz	Sm=53.4 EPG 17.1 eggs/10mL	60-70	PZQ	40	21 days	12 - 17yrs
14	Belizario et al. 2007	RCT	Philippines	Sj	1. Adverse events 2. Cure rate 3. Egg reduction rate	Kato-Katz	≥ 100 EPG	13.5 and 29.2	PZQ	60	24 hours	SAC
15	Berhe et al. 1999	nRCT	Ethiopia	Sm	1. Adverse events 2. Cure rate 3. Egg reduction rate	Kato-Katz Questionnaire	216.3 EPG	NR	PZQ	40	24 hours	SAC
16	Bornmann et al. 2001	RCT	Gabon	Sh	1. Adverse events 2. Cure rate 3. Egg reduction rate	Urine filtration	32 eggs/10mL	80	PZQ+ Artesunate	40	56 days	SAC
17	Braae et al 2016	NR	Tanzania	<i>Taenia solium</i>	Adverse events	Kato-Katz			PZQ	10		
18	Branchini et al. 1982	RCT	Brazil	Sm	1. Cure rate 2. Adverse events	Kato-Katz	24 – 500 EPG >501 EPG	Hospital setting	PZQ	40	6 months	SAC/ADULT
19	Bustinduy et al. 2016	RCT	Uganda	Sm	1. Adverse events 2. Cure rate 3. Egg reduction rate 4. Pharmacodynamics 5. Pharmacokinetics	Kato-Katz	950.4 EPG (40 mg/kg group) 491.0 EPG (60 mg/kg group)	NR	PZQ	40/60	24 hours	PSAC/SAC
20	Carvalho et al. 1984	MDA	Brazil	Sm	1. Adverse events 2. Toxicity 3. Cure rate	Kato-Katz	NR	Hospital setting	PZQ	40/50	6 months	SAC/ADULT
21	Cherit et al. 2014	Case series	Israel	Sm+Sh	Birth outcomes	ELISA	NR	NR	PZQ <sup>o</sup>	60	NR	ADULT

medRxiv preprint doi: <https://doi.org/10.1101/2022.03.09.22270839>; this version posted March 12, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](#).

				+Sj+Smek		Merthiolate-iodine- formaldehyde							
22	Coulibaly et al. 2012	RCT	Cote d'Ivoire	Sm+Sh	1. Adverse events 2. Cure rate 3. Egg reduction rate	Kato-Katz Urine filtration	1.0 eggs/10ml	20 (PSAC) 70 (SAC)	PZQ	40	24 hours	PSAC	
23	Coulibaly et al. 2017	RCT	Cote d'Ivoire	Sm	1. Adverse events 2. Cure rate 3. Egg reduction rate	Kato-Katz CCA	NR**	NR	PZQ	20/40/60	24 hours	PSAC	
24	Coutinho et al. 1983	RCT	Brazil	Sm	1. Adverse events 2. Cure rate 3. Egg reduction rate	Kato-Katz	<100 EPG 100-499 EPG 500-999 EPG 1000-5000 EPG >5000 EPG	NR	PZQ	50 (25x2)	48 hours	SAC/ADULT	
25	Da Cunha et al. 1987	RCT	Brazil	Sm	1. Adverse events 2. Cure rate 3. Egg reduction rate	Kato-Katz	Mean=3382 EPG Median=3195 EPG	Hospital setting	PZQ	60 (20x3)	12 hours	SAC	
26	da Cunha and Pedrosa 1986	RCT	Brazil	Sm	1. Adverse events 2. Cure rate 3. Egg reduction rate	Kato-Katz	>5000 EPG 3000-5000 EPG 2000-3000 EPG 1000-2000 EPG	Hospital setting	PZQ	65	48 hrs	ADULT	
27	da Silva et al. 1981	nRCT	Brazil	Sm	1. Adverse events 2. Cure rate 3. Egg reduction rate	Kato-Katz	<100 EPG <500 EPG 500-1000 EPG >1000 EPG	NR	PZQ	40	1 week	SAC/ADULT	
28	da Silva et al. 1986	RCT	Brazil	Sm	1. Adverse events 2. Cure rate 3. Egg reduction rate	Kato-Katz	>100 EPG < 100 EPG	Hospital setting	PZQ	55	1 week	ADULT	
29	Davis et al. 1981	RCT	Zambia	Sh	1. Adverse events 2. Cure rate 3. Egg reduction rate	Urine filtration	60-250eggs/10mL 251-500eggs/10mL >500 eggs/10mL	NR	PZQ	40 (20 x 2) 60 (20 x 3)	24 months	SAC/ADULT	
30	Debessai & Russom	nRCT	Eritrea	NR	1. Adverse events	NR	NR	NR	PZQ, PZQ + MEB, PZQ + ALB	600-2400 mg	NR	SAC/ADULT	
31	de Quieroz et al. 2010	RCT	Brazil	Sm	1. Cure rate 2. Adverse events	Kato-Katz	203.9 EPG	0.225	PZQ	80	48 hours	SAC/ADULT	
32	De Clercq et al. 2002	nRCT	Senegal	Sh	1. Adverse events 2. Cure rate 3. Egg reduction rate 4. Prevalence	Urine filtration	>5 0eggs/10mL >50 eggs/10mL	90 51	PZQ	40	24 weeks	SAC	
33	Ejezie and Okeke 1987	nRCT	Nigeria	Sh	1. Adverse events 2. Cure rate 3. Egg reduction rate	Kato-Katz	1-100 eggs/10mL	78.1	PZQ	40 (20x2)	18 months	SAC	
34	El-Alamy et al. 1981	nRCT	Egypt	Sm+Sh	1. Side effects	Kato-Katz Urine filtration	NR	40.5 (Sm) 27 (Sh)	PZQ	40	48 hours	PSAC	
35	el Guiniady et al. 1994	RCT	Egypt	Sm	1. Pharmacokinetics 2. Efficacy 3. Side effects	Rectal snip Liver biopsy	NR	NR	PZQ	40	24 hours	NR	
36	El Hawey et al. 1990	nRCT	Egypt	Sm+Sh	1. Side effects	Urine filtration	NR	NR	PZQ	40	36 hours	SAC	
37	Elliot et al. 2007	RCT	Uganda	Sm	1. Prevalence	Kato-Katz	NR	18.3	PZQ	40	48 weeks	PSAC/ADULT	
38	El Masry et al. 1988	RCT	Egypt	Sm+Sh	1. cure rate 2. side effects	Kato-Katz Urine filtration	Sm= 352 EPG Sh=708 eggs/10mL	NR	PZQ	60 (20x3)	NR	NR	
39	Erko et al. 2012	nRCT	Ethiopia	Sm	1. Cure rate 2. Adverse events 3. Egg reduction rate	Kato-Katz	268 EPG	80.6%	PZQ	40	24 hours	SAC/ADULT	
40	Farid et al. 1988	nRCT	Egypt	Sm	NR	NR	NR	NR	PZQ +Prednisolone	75 (25x3)	NR	SAC	
41	Fernandes et al. 1985	RCT	Kenya	Sh	1. Cure rate 2. Adverse events 3. Egg reduction rate	Kato-Katz	N/A	N/A	PZQ	70(70x1) 70 (35x2)	6-8 hours	??	

medRxiv preprint doi: <https://doi.org/10.1101/2022.03.09.22270839>; this version posted March 12, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

42	Ferrari et al 2003	RCT	Brazil	Sm	1. Cure rate 2. Side effects	Kato-Katz Sedimentation	3920 EPG	NR	PZQ	60 x 3	6 months	SAC/ADULT
43	Fletcher & Teklehaimanot 1989	nRCT	Ethiopia	Sm	1. Morbidity 2. Side effects	Kato-Katz	<100 EPG 133-432 EPG >432 EPG	38	PZQ	40	24 hours	PSAC/SAC/ADULT
44	Fu-Yuan et al. 1984	RCT	China	Sj	1. Cure rate 2. Adverse events	Circumoval precipitin test Rectal biopsy Stool miracidia	1 to >20 miracidia per 20g faeces	NR	PZQ	60 (10x6)	1 week	ADULT
45	Garba et al. 2013	nRCT	Niger	Sm+Sh	1. Cure rate 2. Adverse events 3. Egg reduction rate	Kato-Katz Urine sedimentation	13. 9/ 10mL (Sh) 3.6 / 10mL (Sh + Sm)	72	PZQ	40	12 months	SAC
46	Groning et al. 1985	nRCT	Yemen	Sm, sh	1. Cure rate 2. Safety	NR	NR	NR	PZQ Biltricide	40	NR	SAC
47	Gryseels et al. 1987	RCT	Burundi	Sm	1. Adverse events 2. Cure rate 3. Egg reduction rate	Kato-Katz	NR	NR	PZQ	40	48 hours	SAC/ADULT
48	Guisse et al. 1997	RCT	Senegal	Sm	1. Cure rate 2. Adverse events 3. Egg reduction rate	Kato-Katz CCA	1-400 EPG 401-1000 EPG 1001-4000 EPG >4000 EPG	NR	PZQ	40	24 hours	SAC
49	Homeida et al. 1989	RCT	Sudan	Sm	1. Cure rate 2. Adverse events 3. Egg reduction rate	Kato-Katz	NR	NR	PZQ	40	6 months	N/A
50	Hou et al. 2008	RCT	China	Sj	1. Cure rate 2. Egg reduction rate 3. Adverse event	Kato-Katz Antibody test Questionnaire	54.6, 81.7, 51.5 and 50.6 EPG resp (Grp A,B,C andD)	NR	PZQ + Artem	60 & 120	4 hours	SAC/ADULT
51	Ishizaki 1979	RCT	Japan	Sj	Adverse events	Rectal biopsies	NR	NR	PZQ	40 (20x2)	NR	ADULT
52	Jaoko et al. 1996	RCT	Kenya	Sm	1. Side effects	Kato-Katz	4 – 4180 EPG	80	PZQ	40	12 hours	SAC
53	Kabatereine et al. 2003	nRCT	Uganda	Sm	1. Coverage of control 2. Side effects	Kato-Katz	NR	60 - 100	PZQ	40	24 hours	
54	Kabatereine et al. 2006	nRCT	Uganda	Sm	1. Side effects	NR	>1000 EPGI	60 - 100	PZQ	NR	72 hours	PSAC/SAC
55	Kardaman et al. 1983	RCT	Sudan	Sm+Sh	1. Failure rate 2. Adverse events	Kato-Katz Urine sedimentation	NR	NR	PZQ	40 (20x2)	1 week	SAC/ADULT
56	Kardaman et al. 1985	RCT	Sudan	Sm+Sh	1. Failure rate 2. Adverse events	Urine sedimentation Teedale and Amin	367 EPG 120 eggs/10mL	NR	PZQ	20	1 week	SAC
57	Katz et al. 1979	RCT	Brazil	Sm	1. Cure rate 2. Adverse events	Kato-Katz	≥100 EPG	NR	PZQ	60 (20x3)	24 hours	ADULT
58	Katz et al. 1981	RCT	Brazil	Sm	1. Cure rate 2. Adverse events 3. Egg reduction rate	Kato-Katz	95-500 EPG 501-1000 EPG >1000 EPG	NR	PZQ	50 (25x2)	24 hours	SAC/ADULT
59	Katz et al. 1982	RCT	Brazil	Sm	1. Cure rate 2. Adverse events	Kato-Katz	42 - 500 EPG 12 - 1000 EPG 6 - 2500 EPG	NR	PZQ	65	NR	SAC
60	Katz et al. 1983	RCT	Brazil	Sm	1. Cure rate 2. Adverse events	Kato-Katz	4-462 EPG (acute) 24-1662 EPG (chronic) 6-882 (undefined)	NR	PZQ	100 (50x2)	NR	ADULT
61	Keiser et al. 2014	RCT	Cote d'Ivoire	Sh	1. Cure rate 2. Adverse events 3. Egg reduction rate	Urine filtration	3.5 eggs/10mL(Gm) 10.9 eggs/10mL (Am)	NR	PZQ	40	24 hours	SAC
62	Leopold et al. 1978	nRCT	Germany	N/A <sup>#</sup>	1. Side effects	N/A <sup>#</sup>	N/A <sup>#</sup>	N/A <sup>#</sup>	PZQ	50	24 hours	ADULT
63	Mamoun 1988	nRCT	Sudan	Sm	1. Cure rate 2. Adverse events 3. Egg reduction rate	Kato-Katz	321 EPG 448 EPG	NR	PZQ	40	48 hours, 1 week	ADULT
64	Massoud et al 1984	RCT	Egypt	Sm	1. Cure rate 2. Adverse events 3. Egg reduction rate	Kato-Katz	<160 EPG 160-400 EPG >400 EPG	80	PZQ	40	6 months	SAC

medRxiv preprint doi: <https://doi.org/10.1101/2022.03.09.22270839>; this version posted March 12, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

65	McMahon and Kolstrup 1979	RCT	Tanzania	Sh	1. Cure rate 2. Adverse event 3. Egg reduction rate	Urine sedimentation	60-250 EPG 251-500 EPG >500 EPG	NR		PZQ	30	24 hours	SAC
66	McMahon 1981	RCT	Tanzania	Sh	1. Cure rate 2. Adverse events	Urine Sedimentation	NR	NR		PZQ	45-50	Up to 2 years	SAC/ADULT
67	McMahon 1983	RCT	Tanzania	Sh	1. Cure rate 2. Adverse events 3. Egg reduction rate	Urine filtration	>250 miracidia/10mL	NR		PZQ	30	24 hours	NR
68	Midizi et al 2008	nRCT	Zimbabwe	Sh	1. Cure rate 2. Adverse events 3. Egg reduction rate	Kato-katz Urine sedimentation	<50 eggs/10mL ≥50 eggs/10mL	50		PZQ	40	24 hours	SAC
69	Minggang et al. 1983	nRCT	China	Sj	1. Side effects	1.Circumoval precipitin 2. Faecal analysis 3. Miracidial hatching	NR	NR		PZQ	45-60/90-120 mg/10mL	4 days	PSAC/SAC/ADULT
70	Minggang et al. 1985	RCT	China	Sj	1. Cure rate 2. Adverse events	Kato-Katz	NR	22%		PZQ	60 (30x2)		SAC/ADULT
71	Ming-he 1991	RCT	China	Sj	1. Egg reduction rate 2. Side effects	Kato-Katz	<100 EPG 100 to 400 EPG > 400 EPG	NR		PZQ	40	24 hours	SAC
72	Mohammed et al. 2008	nRCT	Tanzania	Sh	1. Side effects	Urine sedimentation	NR	63.5 43.0		PZQ +IVM+ALB	40	1 week	SAC/ADULT
73	Muhumuza et al. 2013	nRCT	Uganda	Sm	1. Uptake of PZQ 2. Side effects 3. Prevalence	Kato-Katz	43.5-668.6 EPG	65		PZQ	40	NR	SAC
74	Mpairwe et al. 2011	RCT	Uganda	Sm	1. Infantile eczema 2. Side effects	Kato-Katz	NR	12.3		PZQ + ALB	40 (PZQ) 400 mg (ALB)	1 year	ADULT
75	Mutapi et al. 2011	nRCT	Zimbabwe	Sh	1. Cure rate 2. Adverse events 3. Egg reduction rate	Kato-Katz Haemoglobin dipstick	14.6 eggs/10mL	21		PZQ	40	24 hours	PSAC
76	N'Goran et al. 2003	nRCT	Cote D'Ivoire	Sh		Urine filtration	29.3 EPG (Gm)	N/A		PZQ	40	N/A	SAC
77	Na-bangchang et al 2006	RCT	Thailand		1.Pharmacokinetics 2. Tolerance			NR		PZQ+IVM+ALB	40	NR	ADULT
78	Nalugwa et al. 2015	RCT	Uganda	Sm	1. Cure rate 2. Adverse events 3. Egg reduction rate	Kato-Katz	1-99 EPG 10-399 EPG ≥400 EPG	NR		PZQ	40	8 months	SAC/ADULT
79	Namwanje et al. 2011a	RCT	Uganda	Sm	Safety of co-administration	Kato-Katz	≤100 – 146 EPG 101–399 EPG ≥400 EPG	21.8		PZQ, PZQ + IVM+ALB	40		SAC
80	Namwanje et al. 2011b	RCT	Uganda	Sm	1. Safety 2. Acceptability	Kato-Katz	GM 84.6 EPG	21.8		PZQ + MEB	40	1 week	PSAC
81	Nash et al. 1982	RCT	USA	Smek, Sm, Sh, Sj	1. Cure rate 2. Adverse events	Kato-Katz	50-5720 EPG	NR		PZQ	60	48 hours	SAC
82	Ndyomugenyi and Kabatereine 2003	nRCT	Uganda	Sm	1. Feasibility 2. Adverse effects	Kato-Katz	NR	30-79.9		PZQ+IVM/MEB	40-60mg/dose pole	NR	SAC
83	Njenga et al. 2014	nRCT	Kenya	Sh	Adverse events	NR	NR	NR		PZQ+ALB	40	48 hours	SAC
84	Niger MDA 1	MDA	Niger	Sm, Sh	Adverse events	10mL urine		>10%		PZQ	30-60 mg/dose pole	7 days	SAC/ ADULT
85	Niger MDA 2	MDA	Niger	Sh	Prevalence Adverse events	10mL urine		>10%		PZQ	40	7 days	SAC/ ADULT
86	Niger MDA 3	MDA	Niger	Sh	Prevalence Adverse events	10mL urine		>10%		PZQ	40	7 days	SAC/ ADULT
87	Niger MDA 4	MDA	Niger	Sh	Prevalence Adverse events	10mL urine		>10%		PZQ	40	7 days	SAC/ ADULT
88	Niger MDA 5	MDA	Niger	Sh	Prevalence Adverse events	10mL urine		>10%		PZQ	40	7 days	SAC/ ADULT
89	Niger MDA 6	MDA	Niger	Sh	Prevalence Adverse events	10mL urine		>10%		PZQ	40	7 days	SAC/ ADULT
90	Niger MDA 7	MDA	Niger	Sh	Prevalence	10mL urine		>10%		PZQ	40	7 days	SAC/ ADULT

medRxiv preprint doi: <https://doi.org/10.1101/2022.03.09.22270839>; this version posted March 12, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](#).

91	Niger MDA 8	MDA	Niger	Sh	Prevalence Adverse events	10mL urine	>10%	PZQ	40	7 days	SAC/ ADULT	
92	Niger MDA 9	MDA	Niger	Sh	Prevalence Adverse events	10mL urine	>10%	PZQ	40	7 days	SAC/ ADULT	
93	Niger MDA 10	MDA	Niger	Sh	Prevalence Adverse events	10mL urine	>10%	PZQ	40	7 days	SAC/ ADULT	
94	Niger MDA 11	MDA	Niger	Sh	Prevalence Adverse events	10mL urine	>10%	PZQ	40	7 days	SAC/ ADULT	
95	Niger MDA 12	MDA	Niger	Sh	Prevalence Adverse events	10mL urine	>10%	PZQ	40	7 days	SAC/ ADULT	
96	Niger MDA 13	MDA	Niger	Sh	Prevalence Adverse events	10mL urine	>10%	PZQ	40	7 days	SAC/ ADULT	
97	Niger MDA 14	MDA	Niger	Sh	Prevalence Adverse events	10mL urine	>10%	PZQ	40	7 days	SAC/ ADULT	
98	Niger MDA 15	MDA	Niger	Sh	Prevalence Adverse events	10mL urine	>10%	PZQ	40	7 days	SAC/ ADULT	
99	Niger MDA 16	MDA	Niger	Sh	Prevalence Adverse events	10mL urine	>10%	PZQ	40	7 days	SAC/ ADULT	
100	Niger MDA 17	MDA	Niger	Sh	Prevalence Adverse events	10mL urine	>10%	PZQ	40	7 days	SAC/ ADULT	
101	Niger MDA 18	MDA	Niger	Sh	Prevalence Adverse events	10mL urine	>10%	PZQ	40	7 days	SAC/ ADULT	
102	Niger MDA 19	MDA	Niger	Sh	Prevalence Adverse events	10mL urine	>10%	PZQ	40	7 days	SAC/ ADULT	
103	Niger MDA 20	MDA	Niger	Sh	Prevalence Adverse events	10mL urine	>10%	PZQ	40	7 days	SAC/ ADULT	
104	Obonyo et al. 2010	RCT	Kenya	Sm	1. Cure rate 2. Adverse events 3. Egg reduction rate	10mL urine	1-99 EPG 100-399 EPG ≥400 EPG	NR	PZQ	40	48 hours	SAC
105	Olds et al. 1999a	RCT	China	Sj	1. Cure rate 2. Adverse events	Kato-Katz	NR	NR	PZQ	60 (sj)	4-6 hours 48 hours	SAC
106	Olds et al. 1999b	RCT	Kenya	Sm, Sh	1. Cure rate 2. Adverse events	Kato-Katz Urine filtration Questionnaire	NR	NR	PZQ	40	4-6 hours 48 hours	SAC
107	Olds et al. 1999c	RCT	Philippines	Sj	1. Cure rate 2. Adverse events	Kato-Katz	NR	NR	PZQ	60	4-6 hours 48 hours	SAC
108	Olliaro et al. 2011a	RCT	Brazil	Sm	1. Cure rate 2. Egg reduction rate 3. Adverse events	Kato-Katz	≥100 EPG	196	PZQ	60 40	4 and 24 hours, 21 days	SAC
109	Olliaro et al. 2011b	RCT	Mauritania	Sm+sh	1. Cure rate 2. Egg reduction rate 3. Adverse events	Kato-Katz Urine filtration	≥100 EPG	186	PZQ	60 40	4 and 24 hours, 21 days	SAC
110	Olliaro et al. 2011c	RCT	Philippines	Sj	1. Cure rate 2. Egg reduction rate 3. Adverse events	Kato-Katz	≥100 EPG	102	PZQ	60 40	4 and 24 hours, 21 days	SAC
111	Olliaro et al. 2011d	RCT	Tanzania	Sm+Sh	1. Cure rate 2. Egg reduction rate 3. Adverse events	Kato-Katz Urine filtration	≥100 EPG	271	PZQ	60 40	4 and 24 hours, 21 days	SAC
112	Olveda et al. 2016	RCT	Philippines	Sj	1. Birth weight 2. low birth weight 3. Maternal anaemia 4. Safety	Kato-Katz	10.0 EPG	NR	PZQ	60 (30x2)	NC	ADULT (Pregnant Women)
113	Omer 1981	RCT	Sudan	Sm+Sh	1. Cure rate 2. Adverse events	Kato-Katz Urine sedimentation	60-250 /10mL 251-500 /10mL >500 /10mL	NR	PZQ	40 (20x2)	48 hours	SAC/ADULT
114	Oyideran et al. 1981	RCT	Nigeria	Sh	1. Cure rate 2. Adverse events 3. Egg reduction rate	Urine filtration	60-250 eggs/10mL 251-500 eggs/10mL >500 eggs/10mL	NR	PZQ	40	24 hours	SAC

medRxiv preprint doi: <https://doi.org/10.1101/2022.03.09.22270839>; this version posted March 12, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](#).

115	Polderman et al. 1984	nRCT	Zaire	Sm	1. Cure rate 2. Adverse events 3. Egg reduction rate	Kato-Katz	173 – 1581 EPG, 775 - 886 EPG	NR	NR	PZQ	40	4 hours	PSAC/SAC
116	Qian 2016	nRCT	China	Sj	Adverse effects	NR	NR	NR	NR	PZQ	*	NR	ADULT
117	Ramiandrasoa et al 2020	??	Madagascar	Ts	Adverse events					PZQ	10		
118	Raso et al. 2004	nRCT	Cote d'Ivoire	Sm	1. Cure rate 2. Adverse events 3. Egg reduction rate	Kato-Katz	1-100 EPG 101-400 EPG >400 EPG	40	40	PZQ	40	24 hours	INFANT
119	Reta et al. 2013	nRCT	Ethiopia	Sm	1. Cure rate 2. Adverse events 3. Egg reduction rate	Kato-Katz FEC	258 EPG	70	70	PZQ	40	24 hours	SAC/ADULT
120	Rezende 1985	RCT	Tanzania	Sm	1. Failure rate 2. Egg reduction rate 3. Adverse events	Kato-Katz	324 EPG < 100 EPG 100 to 500 EPG 501 to 1000 EPG >1000 EPG		Hospital setting	PZQ	55	24 hours	SAC/ADULT
121	Rugemalila et al. 1984	RCT	Tanzania	Sm	1. Adverse events 2. Symptoms resolution	Formal ether	NR	NR	NR	PZQ	40	24 hours	SAC
122	Santos et al. 1979	RCT	Philippines	Sj	1. Failure rate 2. Egg reduction rate 3. Adverse events	Kato katz	50-100 EPG	NR	NR	PZQ	50	1 year	12 months
123	Santos et al. 1984	RCT	Philippines	Sj	1. Failure rate 2. Egg reduction rate 3. Adverse events	Kato-Katz	NR	NR	NR	PZQ	60 (30x2)		SAC/ADULT
124	Schutte et al. 1983	RCT	South Africa	Sm+Sh	1. Failure rate 2. Egg reduction rate 3. Adverse events	Urine filtration	NR	NR	NR	PZQ	40	48 hours	SAC
125	Sissoko et al. 2009	RCT	Mali	Sh	1. Failure rate 2. Egg reduction rate 3. Adverse events	Urine filtration	41.4 EPG (Gm)	70	70	PZQ	40	48 hours	SAC
126	Smith et al. 1981	RCT	Kenya	Sm	1. Acceptability 2. Adverse effects	Kato-Katz	>100 EPG	NR	NR	PZQ	40	12 hours	N/A
127	Sousa-Figueiredo et al. 2010	nRCT	Uganda	Sm	1. Cure rate 2. Adverse events 3. Egg reduction rate	Kato-Katz CCA	5.721 EPG 0.795 EPG	16-44.3	16-44.3	PZQ	40	24 hours	PSAC
128	Stelma et al. 1995	nRCT	Senegal	Sm	1. Cure rate 2. Adverse events 3. Egg reduction rate	Kato-Katz CCA	646 EPG (Gm)	91	91	PZQ	40	24 hours	NR
129	Sukwa 1993	RCT	Zambia	Sm	1. Cure rate 2. Egg reduction rate 3. Reinfection rate 4. Side effects	Kato-Katz	354.8 EPG 336.6 EPG	NR	NR	PZQ	40	12 months	SAC
130	Taddese and Zein 1988	RCT	Ethiopia	Sm	1. Cure rate 2. Egg reduction rate 3. Adverse event	Kato-Katz	129.6 EPG	30	30	PZQ	40	48 hours	SAC/ADULT
131	Tweyongyere et al. 2008	RCT	Uganda	Sm	1. Cytokine responses 2. Side effects	Kato-Katz	NR	NR	NR	PZQ	PZQ	12 weeks	ADULT
132	Watt 1986	nRCT	Philippines	Sm	Side effects	NR	NR	NR	NR	PZQ	60 (20x3)	4 hours	NR
133	Watt et al. 1988	nRCT	Philippines	Sj	1. Pharmacokinetics 2. Side effects	Kato-Katz Rectal biopsy Circumoval precipitin	NR	NR	NR	PZQ	60 (20x)	2 weeks	N/A
134	Wilkins and Moore 1987	RCT	Gambia	Sm+Sh	1. Cure rate 2. Egg reduction rate 3. Adverse event	Urine filtration	1445-1589 /10ml 297-342 /10ml	NR	NR	PZQ	40	24 hours	SAC

medRxiv preprint doi: <https://doi.org/10.1101/2022.03.09.22270839>; this version posted March 12, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](#).

RCT= Randomized Controlled Trial, nRCT=non-randomized clinical trial, Sm =*S. mansoni*, Sh = *S. haematobium*, Sj=*S. japonicum*, Si=*S. intercalatum*, Smek=*S. mekongi*, CCA=Circulating Cathodic Antigen, NR=not reported, PZQ=praziquantel, EPG=eggs per gram, SAC=school age children, PSAC=pre school age children, Gm=geometric mean, Am=arithmetic mean

medRxiv preprint doi: <https://doi.org/10.1101/2022.03.09.22270839>; this version posted March 12, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](#) .

## Commonly reported PZQ AEs

The commonly reported AEs have been presented (see Table 2). Overall, 75 studies involving 33550 participants that investigated PZQ reported incidence of abdominal pain as the leading AE experienced by persons treated with PZQ. This was followed by headache (68 studies, n = 25986 participants), vomiting (66 studies), dizziness (61 studies, n = 20716 participants), diarrhoea (59 studies, n > 18595), nausea (56 studies, n = 19009 participants), fever (36 studies, n = 23096 participants), itching (34 studies, 16247 participants) and somnolence (23 studies, n = 12805) in that order (Table 2). Two hundred and eighty-nine thousand twenty-four (289024) adverse events were recorded across the 134 studies included in this systematic review. Praziquantel administered alone accounted for 188809 of the adverse events whereas PZQ in combination with other drugs produced 99912 events. All the studies reported mild-to-moderate adverse events that resolved on their own. Some studies reported severe adverse events but all resolved on their own without further intervention. A total of 40 serious SAEs were reported among the general population. Some studies did not define or describe the nature of the AEs.

**Table 2** Commonly reported adverse experienced by persons who received PZQ treatment alone or in combination with other drugs (ALB, MEB, IVM) arranged according to number of studies

Adverse event	No. of studies	No of studies by Species					Total adverse events	Adverse events by treatment		Serious AE's
		Sm	Sh	Sm+Sh	Sj	S. mek		PQZ alone	PQZ + other*	
Abdominal pain	75	43	12	10	8	0	33550	33225	325	0
Headache	68	36	14	4	8	1	25986	21414	4572	0
Vomiting	66	36	12	10	5		"	"	??	1
Dizziness	61	30	19	7	4	0	20716	14729	5987	0
Diarrhoea	59	33	13	9	2	1	18595	11659	6936	2
Nausea	56	32	14	6	3	0	19009	11653	7356	9
Fever	36	20	8	5	1	1	23096	10537	12559	0
Itching	34	19	8	2	3	1	16247	6179	10068	0
Somnolence	23	11	6	1	2	1	12805	6820	5985	0
Rash	23	11	4	4	2		43500	31493	12007	25
Fatigue	18	8	2	3	3	0	10662	5108	5545	0
Anorexia	17	7	5	1	3	1	10580	2860	7720	5
Urticaria	13	12	0	0	0	1	2229	1365	771	0
Blood in stool	9	5	0	1	3	0	14235	7245	6990	0
Myalgia	9	4	2	1	0	1	13386	1435	11951	0
vertigo	8	3	3	0	2	0	1652	1263	389	0
Asthenia	8	7	1	0	0	0	2201	1665	536	0
Malaise	8	5	1	1	0	1	765	736	29	0
Bitter taste	7	7	0	0	0	0	852	852	0	0
Cough	7	4	1	2	0	0	4234	3847	186	0

\*co-administered PZQ with other drugs (ALB, MEL, IVM); AEs=serious adverse events, Sm = *S. mansoni*, Sh = *S. haematobium*, Sj =*S. japonicum*, Smek =*S. mekongi*

## **Praziquantel versus placebo**

An RCT is the only design that is able to ascertain the true experience of adverse events because it is able to control for confounding effects/events. Eight RCTs, four conducted in Africa (Borrmann et al. 2001; Jaoko et al. 1996; Olds et al. 1999; Tweyongyere et al. 2009) and the other four in the Americas, all conducted in Brazil (Branchini et al. 1982; Ferrari et al. 2003; Katz et al. 1979a; Katz et al. 1979b) assessed PZQ 40 mg/kg or higher doses and reported mild-to-moderate and transient AEs (Table 3). None reported any serious event. Olds et al. 1999 recorded 15% excess of mild to moderate AEs events with PZQ compared with placebo, and Borrmann et al. 2001 assessed PZQ, Artesunate and placebo and reported combined events across comparison groups (127 mild and 6 moderate events). No SAEs were recorded. The rest of the results have been presented in Table 3.

## **Divided doses of PZQ**

Eighteen studies (Bada et al. 1988; Bustinduy et al 2020; Ejezie and Okeke 1987; Da Cunha et al 1983; Da Cunha et al 1987; El-Masry et al. 1988; Farid et al 1988; Fernandes et al. 1985; Fu-Yuan et al 1984; Ishizaki 1979; Kardaman et al 1983; Katz et al. 1979; Katz et al. 1981; Minggang et al 1985; Olveda et al. 2016; Omer et al 1981; Santos et al 1984; Watt et al. 1986; Watt et al. 1988) assessed various divided doses of PZQ across different endemic settings and schistosome types (Table 4). Fourteen of the studies were RCTs, two cohort studies, one case study and one did not report the type of study design. Various dose schedules were assessed including 40 mg/kg administered as a divided dose of 20 mg/kg x2, 50 mg/k (administered as 25mg/kg double doses), 60 m/kg (as a divided dose of 30 mg/kg or 20 mg/kg taken same day), 75 mg/kg (at 25 mg/kg x 3) and very high doses of 180 mg/kg in divided doses (Table 4). Most of the studies reported minor adverse events, predominantly headache, vomiting, abdominal pain, dizziness and nausea. Some studies reported severe (Bustinduy et al 2020; Da Cunha et al 1986; Olveda et al. 2016; Santos et al 1984; Watt et al. 1986) or serious SAEs (Bada et al. 1988; Minggang et al 1985; Olveda et al. 2016), with the highest incidence of AEs recorded in patients who received higher doses. Studies assessing PZQ 40 mg/kg and comparing with higher doses have been reported in Table 5 -supplementary table.

**Table 3** Adverse events associated with PZQ in comparison with placebo in RCTs

Study ID	Country	N	PZQ dose (mg/kg)	Adverse events	SAE
<i>S. mansoni</i>					
Jaoko et al. 1996	Kenya	436	40x1	Minor and transient adverse events. PZQ versus placebo: Dizziness: 36% vs 6% Abdominal pain 35% vs 14 %	None reported
Katz et al. 1979a	Brazil	55	40 (20x2) 60 (20x3)	Minor adverse events, did not differ between intervention and placebo groups Adverse events were not reported separately for the different dose schedules.	None reported
Katz et al. 1979b	Brazil	61	50x1 60 (20x3)	Adverse events were minor, did not differ between the two groups, but were not reported separately for the two dosing schedules.	None reported
Olds et al. 1999	Kenya	174	40x1	PZQ versus placebo: Abdominal pain: 80% vs 50% Diarrhoea: 54% vs 25%	NR
Tweyongyere et al. 2009	Uganda	387	40x1	Adverse events were minor and transient. The authors pooled adverse events together over the intervention and placebo groups. Event rates were not reported.	None reported
Branchini et al. 1982	Brazil	70	41.2-51.6	Mild and transient AEs PZQ versus placebo in that order: Dizziness: 46.9% (placebo group not reported). Abdominal pain: 24.5% vs 17.6%	None reported
Ferrari et al. 2003	Brazil	72	180 (60x3)	Mostly headache, dizziness, drowsiness and abdominal pain with no apparent differences between the arms.	None reported
<i>S. haematobium</i>					
Borrmann et al. 2001	Gabon	300	40	127 mild and 6 moderate events. Abdominal pain: (14%) Headache: (12%)	None reported
Olds et al. 1999	Kenya	380	40 40+ALB	Adverse events mild to moderate. PZQ: 15% (PZQ) vs 20% (PZQ + ALB)	None reported

N= number of participants, SAE=serious adverse event; ALB=Albendazole;

**Table 4 Adverse events with divided doses of PZQ**


Study and country	Design	Species	PZQ dose	N	Adverse events	Serious adverse events
Bada et al. 1988 Spain	Case study	Sm	40 (20x2)	1	Patient experienced “tonic-clonic convulsive seizure” after treatment.	Seizure, but patient had a history of convulsion
Bustinduy et al 2020 Philippines	RCT	Sj	60 (30x2)	47	Mostly fever, headache, malaise, abdominal pain, vomiting, bloody stools, rash, dizziness etc. which were mild to moderate and self-limiting. Only 2 severe events (headache and malaise).	None reported
Da Cunha et al 1986 Brazil	RCT	Sm	50 (25x2)	27	37% of patients had AEs with 12.5% classified as ‘severe’. General malaise (22.2%), heartburn (18.5%), dizziness (18.5%) and nausea (14.8%). One report of eosinophilic pneumonitis, Loefler syndrome was diagnosed by X-Ray and laboratory assessment in a patient 5 days post-treatment	None reported
Da Cunha et al 1987 Brazil	RCT	Sm	180 (30x2 daily for 3 days 180 (30x1) daily for 6 days 120 (30 x2) daily for 2 days 60 (30x2 in 1 day)	79	Higher proportions with adverse events but all were minor and transient events. Dizziness: 65%, 15%, 45%, 15% Nausea: 55%, 15, 20%, 20% Some AEs were classified as severe The highest incidence of AEs was recorded in patients who received 60 mg/kg daily for 3 days treatment, significantly higher than in those who were treated with 30 mg/kg daily for 6 days	None reported.
El-Masry et al. 1988 Egypt	RCT	Sm, Sh	60 (20x3)	204	Epigastric pain was the most common AE (up to 66.6% of participants who received 20 mg twice daily for 3 days), headache, nausea, vomiting and fever up to 38°C were also common	None reported
Farid et al 1988 Egypt	Not stated	Sm	75 (25x3)	25	The authors first managed the fever and toxemia in the patients before treating with PZQ to avoid serious AEs	None reported
Fernandes et al. 1985 Kenya	RCT		70 (35x2)			
Fu-Yuan et al 1984 China	RCT	Sj	60 (10x6)	716	Of the 476 with chronic schistosomiasis, 299 (62.8%) had AEs; dizziness (112), headache (73), abdominal pain (48), blurring of vision (11)	None reported
Ishizaki 1979 Japan	RCT		40 (20x2); 60 (20x3)	51	14% in Grp1, 12.5% in Grp2 and 58% in Grp3 had AEs such as drowsiness, constipation, headache, etc. AEs disappeared within 24hrs AEs higher in patients treated with 20x3mg/kg dose AEs were also high in placebo group as well.	None reported
Kardaman 1983 Sudan	RCT	Sm, Sh	40 (20x2)	171	45% had complaints; abdominal pains (13%), vomiting (7.5%), diarrhoea (7.5%), urticaria (11%), headache (7.5%), fever (7.5%). All events resolved within 24 hours	None reported
Katz et al. 1979 Brazil	RCT	Sm	40 (20x2) 60 (20x3)	50	In the double-blind trial, 88% of patients treated with 20x2 dose had AEs; 62% of patients treated with 30x2 had AEs. 70% of patients treated with 30x2 PZQ had AEs	None reported
Katz et al. 1981 Brazil	RCT	Sm	50 (25x2)	46	82.6% experienced AEs. AEs were chiefly abdominal distress, giddiness and headache. AEs were slightly higher in SAC than adults (83% and 81%)	None reported
Minggang et al 1985 China	RCT	Sj	60 (30x2) 70(<15yrs) 90-120 (over six days)	25693	.Majority of patients who had SAEs had pre-existing conditions. Events included: Neuropsychiatric events (n=39) Cardiovascular events (n=37) Hepatic changes (n=4) Dermatological events (n=18) Delayed reactions leading to fatigue work (n=29)	122 (0.47%) relatively serious AEs

Olveda et al. 2016 Philippines	RCT	Sj	60 (30x2)	186	5 cases of severe AEs were recorded 24hrs post-treatment	18 events in mothers and 27 events in the foetuses. AEs not likely to be associated with PZQ treatment
Omer et al 1981 Sudan	RCT	Sm, Sh	40 (20x2)	52	Adverse events were transient and required no additional intervention.	None reported
Santos et al 1984 Philippines	RCT	Sj	60 (30x2)	6134	67.8% patients had AEs of which 85% were mild, 13.7% moderate and 1.2% severe. AEs were mostly abdominal pain, dizziness, headache, bloody stools, vomiting, fever, etc. The severe AEs were mainly abdominal pain and started within 1 hour after treatment	None reported
Watt et al. 1986 Philippine s	Cohort	Sj	60 (20x3)	20	4 patients had abdominal pain which progressed to bloody diarrhoea. The affected patients had occult blood in pre-treatment stool and severe liver disease, considered as risk factors for developing post-OZQ bloody diarrhoea	None reported
Watt et al. 1988 Philippines	Cohort	Sj	60 (20x3)	30	All patients experienced mild transient side effects. Drowsiness was the most common followed by headache and then abdominal pain. AEs were found to be associated with elevated plasma concentrations of PZQ	None reported

**Sh:** *Schistosoma haematobium*      **Sm:** *Schistosoma mansoni*      **Sj:** *Schistosoma japonicum*      **Si:** *Schistosoma intercalatum*  
**Sm:** *Schistosoma mekongi*, N=number of participants

## Diarrhoea


The praziquantel 40 mg/kg group experienced a 2% reduced Praziquantel 40mg/kg did not show an increased odd of an individual developing diarrhea compared to Praziquantel 60mg/kg. Belizario 2007 reported relatively high adverse events following PZQ administration but also suggested that, this could have also been due to the parasitic infection. Coulibaly 2007 also did report no difference in the incidence of adverse events in all treatment groups of either school-aged children or pre-school-aged children.



**Fig 5** Forest plot showing the odds of diarrhea between praziquantel 40mg/kg vs Praziquantel 60mg/kg

## Vomiting


The results indicate that individuals receiving Praziquantel 40mg/kg are 57% less chance of vomiting compared to individuals receiving Praziquantel 60 mg/kg (OR= 0.43; CI= 0.43 - 1.29). In two of the three studies (Belizario et al 2007; Olliario et al 2011), adverse events were assessed as probably or most probably caused by PZQ chemotherapy and the cumulative prevalence of adverse events was found to be significantly different between those that received 40mg/kg and 60mg/kg. Characterizing the incidence of adverse effects by time elapsed post-treatment, Olliario et al 2011 reported that 2% and 1% in the 40mg/kg and 60mg/kg treatment groups respectively, reported severe vomiting at 4 hours post-treatment. At 24 hours post-treatment, 14% and 33% reported vomiting with a moderate intensity.



**Fig 6** Forrest plot showing the odds of vomiting between Praziquantel 40mg/kg vs Praziquantel 60 mg/kg

## Headache


The meta-analysis suggested that there is no significant difference between the odds of having a headache following treatment with PZQ either at a dose of 40 mg/kg or 60 mg/kg (OR=0.99, CI= 0.74 - 1.33). Belizario et al, 2007 recorded the same number of reports of headache in both groups of the study (31 events in each group). In the two other studies that compared adverse events in 40mg/kg and 60mg/kg, the number of reports of headache following treatment with PZQ did not differ significantly (6 and 11 in Coulibaly et al 2017, 73 and 69 in Olliario et al 2011).



**Fig 7** Forest plot showing the odds of experiencing headache between Praziquantel 40mg/kg vs Praziquantel 60mg/kg

### Praziquantel 40 mg/kg vs Placebo

Two studies made this comparison (Coulibaly 2017; Schutte et al 1983). Coulibaly et al 2017 compared safety and efficacy of PZQ at 40 and 60 mg/kg in PSAC and SAC. They reported that in both PSAC and SAC treatment groups, diarrhea was one of the commonly reported adverse events when assessed at 3 - 4 hours post-treatment. Schutte et al 1983 studied the efficacy of PZQ administered at 40 mg/kg in children aged between 7 and 17 years. In their assessment of adverse events immediately and 48 hours post-treatment, they reported that adverse events were common in the treatment groups compared to the placebo. From the meta-analysis, there is a 60% increased odds of diarrhea in the PZQ treatment group compared to the placebo (OR= 1.60, CI= 0.29 - 8.66).



**Fig 8** Forest plot showing the odds of diarrhoea between praziquantel 40mg/kg and placebo

### ***Schistosom mansoni* and *S. haematobium* mixed infection**

Thirteen studies (Ahmed et al. 1988; Al-Aska et al. 1990; Anto et al. 2011; Barda et al. 2016; Coulibaly et al. 2012; El-Hawey et al. 1990; El-Masry et al. 1988; El-Alamy et al. 1981; Garba et al. 2013; Groning 1985; Kardaman et al. 1983; Omer et al. 1981; Schutte et al. 1983) involving eight RCTs (Al-Aska et al. 1990; Anto et al. 2011; Barda et al. 2016; Coulibaly et al. 2012; El-Masry et al. 1988; Kardaman et al. 1983; Omer et al. 1981; Schutte et al. 1983), three clinical trials (El-Hawey et al. 1990; El-Alamy et al. 1981; Garba et al. 2013, one MDA (Groning 1985) investigated adverse events of PZQ in mixed infection with *S. amsoni* and *S. haematobium*. One study (Ahmed et al. 1988) did not state the study design. The studies pooled did not record any SAEs; all events were mild-to-moderate and transient (Table -supplementary file).


### **Adverse events between SAC and Adults**

Twenty studies involving over one million (1,100,992) participants assessed adverse events associated with PZQ 40 mg/kg and reported abdominal pain, diarrhoea, headache, nausea, vomiting, dizziness, allergy, anorexia and fever as the most frequently experienced adverse events, and arranged in a decreasing incidence (Table 7). Adverse events were mostly mild-to-moderate and transient, resolving few hours after treatment. There were reports of some severe events but these were non-life threatening and did not require further intervention. No serious event was recorded. Risk ratios, CIs and p-values obtained from the meta-analyses have been reported (Table 7). Children experienced higher frequencies of all the adverse events, and the risk ratios were statistically significance over events in adults, except swelling where there was not apparent difference in incidence between SAC and adults. Overall, 23,939 incidence of headache (20004 out of 694530 SAC and 3937 out of 406462 adults treated with 40 mg/kg PZQ) was recorded. The pooled risk ratio (RR) showed a three times increased risk of headache following PZQ treatment in SAC than adults (RR 3.07, 95% CI 2.32 to 4.06, n=1,100,992, twenty studies,  $I^2=98\%$ ,  $p<0.00001$ ) (Fig 10). Homogeneity between studies (measured by the  $I^2$ ) was very high (98%). Dizziness was the next frequently reported adverse event and the incidence was much higher in SAC than adults (RR 1.80, 95% 1.36 to 2.37, n=1,100,992, twenty studies,  $I^2=98\%$ ;  $p=0.0001$ ) (Fig 11). Vomiting formed about 14% of all adverse events reported with higher risk (2.5 times) of experiencing an event in SAC than adults (RR 2.43, 95% CI 1.87 to 3.14,  $I^2=98\%$ ;  $p<0.00001$ ) (Fig 12). The risk of experiencing an adverse event was higher in SAC than adults for abdominal pain (RR 3.97, 95% CI 3.09 to 5.10,  $I^2 = 96\%$ ,  $p< 0.00001$ .), nausea (RR 1.67,


95% CI 1.32 to 2.12,  $I^2=97\%$ ,  $p < 0.0001$ ), general discomfort (RR 1.32, 95% CI 1.03 to 1.68,  $I^2=97\%$ , 0.00001), fever (RR 4.78, 95% CI 3.04 to 7.52, twenty studies,  $I^2=98\%$ ,  $p < 0.00001$ ), diarrhoea (RR 1.41, 95% CI 1.12 to 1.78, twenty studies,  $I^2=92\%$ ,  $p < 0.00001$ ), Itching (RR 2.42, 95% CI 1.58 to 3.70, twenty studies,  $I^2=93\%$ , 0.0001), breathing difficulty (RR 2.46, 95% CI 1.41 to 4.29, twenty studies,  $I^2=92\%$ , 0.002) and swelling (RR 1.15, 95% CI 0.98 to 2.31, twenty studies,  $I^2=85$ , 0.06). One study (MDA15) did not have any event in the adult arm for both headache and dizziness hence the wide confidence intervals (Fig 10 and Fig 11). See supplementary documents for figures 12 to 20.

**Table 7** Incidence of adverse events with the standard 40 mg/kg single dose PZQ pooled from 20 studies involving over one million treated persons

Adverse event	Adverse events		Total	Percent (%)	Risk Ratio	Confidence interval (CI)		p-value
	SAC	Adults				SAC + Adults	Lower	
Headache	20004	3937	23939	19.1	3.07	2.32	4.06	<0.00001
Dizziness	13597	5281	18878	15.1	1.80	1.36	2.37	<0.0001
Vomiting	13986	4074	18060	14.4	2.43	1.87	3.14	<0.00001
Abdominal pain	12572	2152	14724	11.4	3.97	3.09	5.10	<0.00001
Nausea	10248	3536	13784	11.0	1.67	1.32	2.12	<0.0001
General discomfort	8785	3902	12687	10.1	1.32	1.03	1.68	<0.00001
Fever	9168	1771	10939	8.7	4.78	3.04	7.52	<0.00001
Diarrhoea	3846	1771	5617	4.5	1.41	1.12	1.78	<0.00001
Itching	1873	755	2628	2.1	2.42	1.58	3.70	<0.0001
Breathing difficulty	1181	405	1586	1.3	2.46	1.41	4.29	0.002
Swelling	741	432	1173	0.9	1.15	0.98	2.31	0.06



**Fig 10** Headache associated with PZQ (40 mg/kg single dose) between school age children and adults in preventive chemotherapy programmes



**Fig 11** Dizziness associated with PZQ (40 mg/kg single dose) between school age children and adults in preventive chemotherapy programmes

## **Adverse events in pregnant and lactating women**

Eight studies (4 RCTs and 4 nRCTs) investigated PZQ use in pregnancy. Of the eight studies, two RCTs (Bustindy et al. 2020; Twenonyere et al. 2009) and 3 nRCTs (Chetrit et al. 2014; Adam et al. 2004; Qian et al. 2016) reported mild to moderate adverse events that were transient. The study by Chetrit et al. 2014 and the RCT by Bustindy et al. 2020 used a higher dose of PZQ at 60 mg/kg. Two RCTs reported a number of serious adverse events with either 40 mg/kg PZQ (Elliot et al. 2007) or 60 mg/kg (Olveda et al., 2016). Elliot et al. 2007 compared PZQ at the standard single dose of 40 mg/kg alone with PZQ plus ALB (400 mg) or PZQ plus placebo or ALB plus placebo. The PZQ plus placebo arm resulted in 4 miscarriages, 13 foetal deaths, 46 low birth weights and 43 congenital anomalies were reported among 626 women who received PZQ during pregnancy. No further details were provided for the type and nature of the congenital anomalies. Similar outcomes occurred in the PZQ plus ALB arm though where 4 miscarriages, 12 foetal deaths, 39 low birth weights and 50 congenital anomalies were reported among 628 women who received PZQ during pregnancy. The ALB + Placebo arm experienced 6 miscarriages, 11 foetal deaths, 45 low birth weights and 42 congenital anomalies among 629 women who were exposed to PZQ during pregnancy. The arm with the inactive ingredient (placebo) also experienced 4 miscarriages, 8 foetal deaths, 46 low birth weights and 42 congenital anomalies. Another RCT (Olveda et al., 2016) that assessed PZQ use during pregnancy compared with Dextrose reported adverse outcomes. This study though used higher PZQ dose schedule at 60 mg/kg administered as a divided dose (30 mg/kg x 2) and compared this with. The PZQ arm experienced 18 serious adverse events including 2 foetal deaths, 1 congenital anomaly and 2 cleft palate among 186 women who received PZQ during pregnancy. The women in the dextrose arm experienced 16 serious adverse events including one congenital anomaly and one cleft palate among 184 women included in the study. The study by Adam et al. 2005 conducted in Sudan and involved 25 pregnant women that assessed, retrospectively, adverse events associated with PZQ during pregnancy reported one miscarriage (Table 8). The dose used in the study was not reported.

**Table 8** Adverse events associated with PZQ administration among 3057 pregnant women

Study ID	Study design	Intervention	Dose (mg/kg)	Pregnant women	Foetal adverse events					
					MISC	Foetal death	LBW	Congenital anomalies	Cleft palate	SAEs
Adam et al. 2004	nRCT	PZQ No PZQ	40 x 1	88						None reported
Adam et al. 2005	nRCT	PZQ	40 x 1	25	1					1 SAE
Chetrit et al. 2014	Case Series	PZQ	60 x 1	10						None reported
Qian 2016	Case series	PZQ	Not reported	6						None reported
TWENONYERE et al. 2009*	RCT	PZQ Placebo	40 x 1	208						None reported
Bustindy et al. 2020	RCT	PZQ	60 (30x2)	15						
		PZQ + ALB	40 +400 mg	628	4	12	39	50		105
		PZQ + Placebo	40 x1	626	4	13	46	43		106
		ALB + Placebo	400 mg	629	6	11	45	45		107
Elliot et al. 2007	RCT	Placebo		628	4	8	46	42		100
Olveda et al. 2016	RCT	PZQ Dextrose	60 (30x 2)	186		2		1	2	5
				184				1	1	2
				<b>3057</b>	<b>19</b>	<b>46</b>	<b>176</b>	<b>182</b>	<b>3</b>	

\*55.3% in the PZQ and 46.7% in the placebo group also received ALB (400mg)

nRCT=non-randomized controlled trial, MISC=miscarriage, LBW=low birth weight, SAE=serious adverse event, PZQ=praziquantel, RCT=randomized controlled trial

### Visual adverse events in PZQ treatment

Five of the included studies were RCTs (Anto et al., 2011; Sissoko et al., 2009; Fu-yuan et al., 1984; Leopold et al., 1978; Rezende, 1985), and one was a case-series assessment study (Debesai & Russom, 2020b). Four of the five included studies were conducted in Africa, specifically Ghana (Anto 2011), Mali (Sissoko 2009), Tanzania (Rezende 1985) and Eritrea (Debesai & Russom 2020), one in China (Fu-yuan 1984) and one other in a non-endemic country in Germany involving healthy volunteers (Leopold 1978). One study assessed self-reported PZQ-related adverse effects in Eritrea (Debesai & Russom 2020). As expected, the study conducted in China was on treatment for *S. japonicum*. Table 8) ummarizes incidence and frequency of visual-related safety issues with PZQ from the four RCTs (Anto et al. 2011; Fu-Yuan et al. 1984; Rezende et al.

1985; Sissoko et al. 2009) and the cohort study (Leopold 1978). The study by Debessai & Russom (2020) has been reported in a separate table (Table 8). The study conducted in Ghana involved participants with *S. mansoni* and *S. haematobium* (Anto et al., 2011), in Brazil involved participants was concerned with *S. mansoni* (Rezende et al. 1985) and that from Mali (Sissoko et al. 2009) involved treatment for *S. haematobium* infections. A range of diagnostic procedures was used in the studies included in this review. They comprised sedimentation (Anto et al. 2011), circumoval precipitin test and rectal biopsy (Fu-yuan et al. 1984), Kato Katz (Rezende et al. 1985) and urine filtration (Sissoko et al. 2009). Three of the six studies included (Anto 2011; Sissoko 2009; Rezende 1985) involved school-aged children whereas two included only adults (Fu-yuan 1985, Leopold 1978). Rezende et al. (1985) included both SAC and adult participants.

Anto et al. (2011) reported incidence of some visual-related adverse events which co-administered PZQ with Albendazole and Ivermectin and compared this with Albendazole plus Ivermectin. A total of 180 adverse events were recorded out of which eight (8) were visual-related. Only eight participants out of 15,552 in the control arm (ALB + IVM) experienced visual-related events. The adverse events were similarly characterised as mild and did not require hospitalization. In the Eritrean study conducted by Debesai & Russom (2020), out of a total of 2579 Individual Case Safety Reports (ICSRs) of PZQ use that were retrieved from the WHO Vigibase database. Of the sixty-one reports confirmed to be visual disorders, 47 occurred in Eritrea following PZQ administration. The authors applied the Austin Bradford-Hill criteria to assess a possible causal relationship between PZQ use and the reported visual disorders and the results were confirmed, the authors concluded that there was a strong association between PZQ use and there was a strong temporally plausible association that was consistent and specific. Leopold et al., 1978 reported a bizarre case of visual disorder in one participant out of the six that received 75 mg/kg of PZQ in divided doses of 25 mg/kg. The authors reported that, one participant complained of a blurry vision and lack of concentration. This event occurred about 30 minutes after the patient received the second dose of PZQ.

**Table 9** Summary of reported visual adverse events in the included RCTs

Study	Mean age (SD)/yrs	Mean weight (SD)/kg	Treatment (Control)	Dose /mg/kg	No. of Visual disorders (N)	Nature of disorder
Anto et al. 2011	12 (2.0)	28.1 (8.51)	PZQ+ALB+IVM versus ALB+IVM	**	8 (6896) *	Reddening of eyes
Fu-Yuan et al. 1984	--	--	PZQ <sup>+</sup>	60	11 (476)	Blurred vision
Rezende et al. 1985	20.6	52.4	PZQ (Oxamniquine)	55	3 (272)*	Blurred vision
Sissoko et al. 2009	10.45	--	PZQ versus AS+SMP	40	1 (392)*	Conjunctivitis
Leopold 1978	--	--	PZQ versus Placebo	25	1 (6)	Blurred vision

\* Visual disorder occurred in the control group AS+SMP (Artesunate + Sulfamethoxyprazine/Pyrimethamine)

\*\* Height-dosage relationship used where; 94–109 cm = 1 tablet; 110–124 cm = 1½ tablets; 125–137 cm = 2 tablets; 138–149 cm = 2½ tablets; 150–159 cm = 3 tablets; 160–177 cm = 4 tablets and ≥178 cm = 5 tablets

<sup>+</sup> Participants were group based on clinical presentation of schistosomiasis (i.e, advanced or chronic, presence of coinfections)

**Table 10** Summary of reported visual adverse disorders from Debesai & Russom (2020)

Sex	Number	Mean age (SD)	Reported visual disorders		
			Blurred vision (%)	Visual impairment	Lacrimation increased
Male	18	23.06 (12.88)	14 (29.8%)	4 (8.5%)	0
Female	29	28.72 (13.37)	21 (44.7%)	7 (14.9%)	1 (2.1%)
Total	47	26.63 (13.33)	35 (74.5%)	11 (23.4%)	1 (2.1%)

### PZQ adverse events in taeniasis

Two studies (Braae et al., 2016; Ramiandrasoa et al 2020) reported on the use of PZQ in treating Taeniasis. In two of the studies (Braae et al 2016 and; Ramiandrasoa et al 2020), the treated species was *Taenia solium* but the species in Hong 2018 was not known as the study relied on data from a drug safety surveillance database where safety issues were self-reported. The two former studies both administered PZQ at the WHO recommended dose of 10 mg/kg for treating Taeniasis, much lower than the 40 mg/kg for treating Schistosomiasis. Hong 2018 reported 108 cases (some events overlapped in people who co-administered Albendazole) of adverse events but it is unclear how many people were treated although the author estimates in excess of 152,000

Korean people between 2012 and 2015. Apparently, only a single case out of the 108 was found to be associated with PZQ treatment. Braae et al 2016 used a “track and treat” approach in administering PZQ to people infected with Taeniasis after a PZQ MDA to treat targeted at treating Schistosomiasis. None of the 20 people treated with 10 mg/kg PZQ experienced any adverse event. Ramiandrasoa et al 2020 recorded adverse events in less than 0.5% in each of the three rounds of MDA that treated 221,308 people. Majorly, nausea and temporary diarrhoea were the reported adverse events.

**Table 10** Adverse events of PZQ after treatment or taeniasis

Study	Country	Worm	PZQ dose	Number treated	Adverse events	Serious adverse events	Remarks
Ramiandrasoa et al 2020	Madagascar	<i>Taenia solium</i>	10 mg/kg	221,308	Minor side effects mainly nausea and diarrhoea. 0.4%, 0.3% and 0.2% of AEs were recorded during the 1 <sup>st</sup> , 2 <sup>nd</sup> and 3 <sup>rd</sup> MDA rounds	None reported	Adverse events were monitored both actively and passively
Braae et al 2016	Tanzania	<i>Taenia solium</i>	10 mg/kg	20	No AEs were recorded during the study but it is unclear how AEs were assessed.	None reported	The study tracked and treated participants infected with Taeniasis after rounds of Schistosomiasis MDA.

N/A=Not applicable, NR=Not reported, MDA= Mass Drug Administration, AEs= Adverse events

### Risk of bias assessment in the included RCTs

Majority of the included RCTs were of good quality methodologically with several studies presenting sufficient details of the methods of the RCTs. Some studies, though, did not report how the random sequence was generated making it difficult to ascertain methodological rigour. Allocation of participants was concealed in a good number of studies using varying methods but mainly through the use of sealed envelopes. Apart from three open-label studies, all other included RCTs reported blinding of either participants, investigators or both in allocation, administering treatments and/or assessing outcomes. Few studies reported substantial loss to follow-ups whereas some studies did not explore the effect of incomplete outcome data on the resultant outcomes. In all the included RCT studies, the reported outcomes or main conclusions were at par with individual study objectives thus reducing reporting bias. To a large extent, no

other biases were identified but, in some studies, sample sizes were relatively small. See Appendix for the results of risk of bias assessment and the authors judgement.

### **Risk of bias assessment in the included cohort studies**

The validity of the design of a cohort study depends on sufficient follow-ups, proper matching and a study without selection bias. If follow-ups are carried out correctly, the exposed and unexposed groups are checked for the outcome. Adequate matching often caters to all potential confounders that can impact the research result. However, the internal validity and strength of the study can be compromised by the impact of losing patients during follow-up in cohort studies. In addition, in designing intervention groups, selection bias is likely to cause a systemic error, allowing them to vary in terms of prognosis.

The sampling source for all the cohort studies was properly carried out with reference to the current review, except for a couple of them who could not identify their sample source. Exposure and outcome are defined as appropriate if the outcome is expected by the exposure. In this respect, the exposure measurement of the sample and the result were satisfactory. For most of the cohort studies, though, matching was not performed. Therefore, the result of the research will be influenced by potential behaviour characteristics. On most of the research, follow-ups were performed adequately, except for a few of them that were inconclusive.

**Table 4** Grading the level of evidence using GRADE

**Population:** People with schistosomiasis  
**Setting:** Schistosomiasis endemic settings  
**Intervention:** PZQ alone or in combination  
**Comparison:** Placebo, no treatment, other schistosome drugs or drugs combined with PZQ  
**Outcome:** Adverse events

Outcomes	Anticipated absolute effects* (95% CI)		Relative effect (95% CI)	Number of participants (studies)	Quality of the evidence (GRADE)
	Without preventive chemotherapy	With preventive chemotherapy			
Serious adverse events*	0	0	-- --	75985 (108 studies)	⊕⊕⊕⊙ Moderate <sup>1</sup>
Dizziness	2 per 100	19 per 100	3.8% (95% CI 3.54% to 4.06%)	20716 (61 studies)	⊕⊕⊕⊙ Moderate <sup>1</sup>
Abdominal pain	4 per 100	66 per 100	16.5% (95% CI 16.1% to 16.9%)	33550 (75 studies)	⊕⊕⊙⊙ Low <sup>1,2</sup>
Headache	3 per 100	39 per 100	13.2% (95% CI 12.79% to 13.61%)	25986 (68 studies)	⊕⊕⊙⊙ Low <sup>1,2</sup>
Diarrhoea	12 per 100	57 per 100	4.8% (95% CI 4.49% to 5.11%)	18,595 (59 studies)	⊕⊕⊙⊙ Low <sup>1,2</sup>

\*Includes stillbirth, congenital anomalies, premature birth or events requiring hospitalization

Adverse events without praziquantel 40 mg/kg varied considerably in the included studies and depended on the outcome assessed. Therefore, outcome-specific risks have been provided.

The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the effect of the intervention (proportion and its 95% CI).

-----  
 GRADE Working Group grades of evidence (Guyatt et al., 2013)

⊕⊕⊕⊕ High quality: We are very confident that the true effect lies close to that of the estimate of effect.

⊕⊕⊕⊙ Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.

⊕⊕⊙⊙ Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.

⊕⊙⊙⊙ Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.

1 Downgraded by 1 for serious risk of bias: The vast majority of the included studies are observational studies with methodological limitations

2 Downgraded by 1 for indirectness: These studies did not specify baseline risk with major events such as diarrhoea, abdominal pain etc. which are common among schistosomiasis infected persons or, for example, headache which is commonly associated with infections other than schistosomiasis

## DISCUSSION

Most of studies reported mild-to-moderate and transient adverse effects indicating that PZQ is safe. Adverse events were mild-to-moderate and transient. From the meta-analyses that compared school age children and adults, there were excesses of adverse events in the SAC groups for all the events analysed but these were mild-to-moderate and no serious event was reported. However, the few studies that assessed safety in pregnant women reported some serious adverse events (miscarriage, foetal deaths and congenital anomalies) which raises safety concerns. Given that those in the non-PZQ arms also experienced serious adverse events in almost similar numbers means that the evidence is inconclusive and further research is warranted. Similarly, the few studies that focused on PZQ-related visual adverse events reported incidence of serious visual adverse events after PZQ treatment, raising further concerns about PZQ. Again, there was limited or no data on long term adverse events (including blood biochemistry and organ pathology), safety in co-morbidity states and co-infection with taeniasis, calling focused and robust analysis targeted to these specific questions. Although this systematic review and meta-analysis included 129 studies, most of them were limited by sample sizes, very short follow-up times that captured only immediate adverse events (missing long term events associated with PZQ use) and methodological rigour. We did not find any study that had investigated safety of PZQ between those with infection and those without infection to compare event rates. This has serious public health implications and raises an important ethical debate as persons without infection who receive PZQ could be very high in some settings where endemicities are going down and the number of persons without infection that get treatment could reach as high as 90% in some communities earmarked for PC. An important observation, is that studies on schistosomiasis adverse events research generally lack methodological rigour in design, methods, conduct and reporting. Given that PZQ is now administered repeatedly in endemic populations, further effort is needed to obtain and assess in detail the aforementioned areas with limited evidence to inform sound guidance and policies in the future.

Considering the severe adverse events, one study (DaSilva et al, 1986) reported 5 cases of severe dizziness associated with PZQ intake but the event subsided within two hours of administration. This study did not explore any causal assessment of the event. In one study (Minggang et al, 1983), 98 serious adverse events including hepatic coma, epileptic seizures, atrioventricular block were reported for treatment for *S. Japonicum*, but the investigators used dose schedules that were

slightly higher (60 mg/kg, 70 mg/kg and 90-120 mg/kg). In this retrospective study, with varying dose schedule, the minimum reported schedule was 45mg/kg and others were as high as 120 mg/kg over extended period of over six days. The investigators reported that those who received PZQ treatment had acute or advanced schistosomiasis. The evidence obtained from this study was inconclusive because some of the participants had other medical conditions such as chronic hepatitis, nephropylitis, neurosis etc. which could confound the association between the praziquantel and the serious adverse events. For example, it was realized that 8patients who experienced seizures were epileptic. Nonetheless the study was retrospective thus reducing the robustness of the evidence. Also, causal assessments could not confirm from this study. Though inconclusive, we are therefore, concerned with the likelihood of serious events when praziquantel is administered to persons with chronic conditions. We thus recommend that administration to persons with underlying other medical conditions such as epilepsy, Hepatitis, etc. should be done with caution.

Another study of interest was Berhe et al, 1999, which recorded some severe adverse events. Berhe reported generally transient and mild symptoms with most of them resolving on their own. However, 90 of the 611 patients experience serious adverse events associated with gastrointestinal disorders such that they were administered antispasmodics and analgesics. This study is a cohort study and causal relationship was not be established, and more so as the variables needed to assess association between PZQ were not properly reported..

### **Meta-Analysis of Events**

A subgroup meta-analysis conducted on 3 studies reveal that individuals taking 40mg/kg of praziquantel are 57% reduced risk of vomiting compared to individuals taking in praziquantel 60mg/kg. Therefore, it is imperative that where there is no evidence of possible resistance to praziquantel or an evidence of impaired renal function, then prescribers should maintain a praziquantel dose of 40mg/kg during management. Since increasing the dose to 60mg/kg may associated with an increased risk of vomiting amongst the patients. The meta-analysis for the comparison of the events such as headache, vomiting and abdominal pain associated with praziquantel administration as against other doses of praziquantel or placebo reveals that there is no increased risk of event with praziquantel compared to the other doses or placebo. Since the included studies were all randomized control trial the meta-analysis is robust. But the number of

trials included in this meta-analysis were not many reducing the power and the reliability of statistically detecting any differences.

The researchers of this review conclude that there is no evidence of serious adverse events associated with praziquantel intake at various doses. Considering the 108 studies that were included in this review, the evidence is that praziquantel is still safe for administration though it may be associated with mild to moderate side effects such as headache, dizziness, diarrhea and abdominal pains. However, these events are highly tolerable and do not require hospitalization. Though most studies included in this review were old and have reduced robustness in the method of conduct, we found little or insufficient evidence to believe that praziquantel is not safe for administration to persons who are not pregnant. We recommend the continuous use of praziquantel 40mg/kg for mass drug administration. The reviewers recommend further investigation on the safety of praziquantel for administration to persons with underlying medical conditions such as neurological disorders, cardiovascular events and other organ damages.

### **Comparison between school age children and adults**

From the meta-analyses that compared school age children and adults, there were excesses of adverse events in the SAC groups for all the events analysed but these were mild-to-moderate and no serious event was reported. However, the few studies that assessed safety in pregnancy reported serious adverse events (miscarriage, foetal deaths and congenital anomalies) to raise safety concerns. Nonetheless, given that those in the non-PZQ arms also experienced serious adverse events in almost equal numbers means that the evidence is inconclusive and further research is warranted. Similarly, the few studies that focused on visual adverse events reported severe visual adverse events raise concerns for further research as this review could not provide answers to the underlying factors. Again, there was limited or no data on long term adverse events (including blood biochemistry), safety in co-morbidity states, mixed schistosome infections and co-infection with taeniasis, calling future focused analysis or new studies generate tailored evidence. Although this systematic review and meta-analysis included 123 studies, most of them were limited by sample size, very short follow-up times that captured only immediate adverse events and missing long term events associated with PZQ use and methodological rigour. We did not find any study that had investigated safety of PZQ between those with infection and those without infection. This raises serious public health concerns and ethical implications as persons without infection who receive PZQ could reach as high as 90% in communities earmarked for preventive chemotherapy. Generally, studies on adverse events in schistosomiasis

as identified in this systematic review lacks methodological rigour in design, methods, conduct and reporting. Given that PZQ is now administered repeatedly in endemic populations, further effort is needed to obtain and assess in detail the aforementioned areas with limited evidence to inform sound guidance and policies in the future.

### **Quality of the evidence**

GRADE methodology was employed in the assessment of the quality of evidence and presented in summary of findings (SOF) tables for the main comparisons. A 4-point scale was used to assess the level of quality of the evidence. High quality evidence implies that researchers have high levels of confidence in the effect estimate and that further research is unnecessary. Moderate quality evidence implies lower confidence in the result and further research may have an important impact on the result. Low and very low-quality evidence shows the increasing ambiguity in the result and an imperative for further research to be conducted. The evidence presented is generally considered to be of moderate or low quality due to concerns related to three key factors: i) most studies included in this review were very old thus reducing the robustness of the findings, ii) there was poor evidence in the reporting of the methods of the included studies resulting in some limitations, iii) poor reporting of adverse events and lack of causal assessment for the reporting of the events and iv) the number and size of the trials being small and often underpowered to reliably detect statistically significant differences.

### **Safety of praziquantel in pregnant women**

Schistosomiasis has become one of the most prevalent parasitic infections and has significant economic and public health consequences. Studies across the globe have reported on the safety of praziquantel in pregnancy. No records of severe human pregnancy adverse effects have been reported over the years of experience with praziquantel. In a retrospective study by Adam et al., (2004) in Sudan, 88 pregnancies with inadvertent exposure to praziquantel, including 37 with exposure during the first trimester, were compared to 549 other pregnancies with no exposure to praziquantel. Clinical examination of babies born to exposed or unexposed women found that none of the 88 exposed pregnancies resulted in abortion or stillbirth and no congenital defects were reported (Adam et al 2004). The challenge with this study is that the study was retrospective and as such, the dose of administration could not be assessed. Since the incidence of adverse event is dependent on drug dosage, it is inconclusive to establish from this study that praziquantel is safe. Again, as stated in the study, the proportion of respondents assessed, 88, was too small to

generalise especially for adverse events that are rare, the incidence of the adverse event may not be observed in this study.

Another prospective study which involved 25 pregnant Sudanese women with *S. mansoni* infections were treated with a single dose of praziquantel, at 40 mg per kg, during different trimesters (Adam et al 2005). While at 10 weeks of gestation, one of these women had a spontaneous abortion, this adverse event cannot be attributed to the intervention because it happened about 3 weeks after administration of praziquantel. We therefore rate this causality assessment as highly unlikely. This is because the rate of abortion among the treated women was close to the baseline rate in the study population. Even in the first trimester of pregnancy, it appeared that PZQ was a safe medication to use against *Schistosomiasis mansoni*. Both studies reported praziquantel is safe in pregnancy, however possible limitations might have affected the outcome or results of the study. In as much as cohort studies are rated very highly in terms of level of evidence for an intervention study, in retrospective cohort studies data collected may not originally collected for the study purpose and hence may be incomplete which could affect the outcome of the study. In addition, they could be a recall bias since participants may give information, which may not be a true reflection of themselves.

For a small case series of schistosomiasis travel-related acquisitions, four pregnant women were treated with 60 mg per kg of praziquantel, including two treated during the first trimester. For mothers or neonates, treatment did not culminate in any significant adverse reactions (Ben-Chetrit et al, 2015). Nonetheless, the case series cannot be generalised because there are several confounding variables that limits the robustness of this study. In the treatment of neurocysticercosis, daily doses of praziquantel for up to 21 days were administered to pregnant women without any apparent adverse events (Paparone 1996).

Considering more robust method of assessing the safety of praziquantel in pregnant women, randomized controlled trials were considered in this review. A trial in Leyte, the first elaborate study of the pharmacokinetics of praziquantel in pregnant women was performed (Bustinduy et al, 2020). The findings of this research, which included assays quantifying the concentrations of praziquantel in the milk of treated women, showed that administration of praziquantel in pregnant women did not present any severe adverse event. The limitation of this study is that the primary outcome was to look at the pharmacokinetics of the drug thus the sample size of the study was

small to generalise the findings of adverse events of this study. For rare adverse events, huge sample size would be required. The recorded adverse events in the Leyte trials included Headache, diarrhoea, fever, apnoea (Table 2). Most of these adverse events were mild and did not pose any threat to the pregnancy of the mothers. Another concern from this study is that the dose of the drug administered is 30mg/kg at 3 hours apart. This dosage is different from the dosage often used for mass drug administration hence the expected incidence of adverse event may differ.

Another trial that assessed the safety of praziquantel in pregnant women is the Entebbe Mother and Baby study. This study assessed pregnant women who had infection and those who did not at a dose 40mg/kg. This design approach and dosage imitates the mass drug administration recommended by the WHO. The Entebbe mother and Baby trial assessed several outcomes and reported as several publications (Elliot et al 2007, Twenyogyere et al 2011, Ndibazza et al 20, Nampija et al 2012, Webb et al 2011, Namara et al 2017). Thus, for this review, the publications were viewed as separate studies. For Elliot et al, report on the safety of praziquantel amongst pregnant women was not stated. Therefore, it is inconclusive to draw the safety of praziquantel amongst these high-risk groups. Due to the robustness of the study and the appropriateness of the method of conduct, the evidence that praziquantel administered to pregnant mothers did not influence anaemia and birthweight of the child. The study observed that there were congenital anomalies and perinatal mortalities, and these were evenly distributed across the arms. However, the study failed to assess the causality of the adverse event.

Olveda et al in a clinical trial conducted in North Eastern of Leyte in Philipines assessing the immunological response of mothers at 12-16 weeks of gestation to praziquantel. This study is powered compared to the Bustindy et al. Olveda reported 18 severe adverse events. The study reported congenital anomalies such as talipes equinovarons and foetal cleft palate. For the club feet, the study identified even distribution of this event in both arms of the study. Yet the incidence of cleft palate was 2:1 in the praziquantel arm against the comparator. A similar anomaly of cleft palate was reported in a case series by Qian et al., which seem to suggest that there could be a potential case of cleft palate induced by praziquantel. Through it all, the study did not establish the causality of these serious adverse events and this is a limitation to this study. Considering the study participants, it can be argued that the participants were within the second

trimester and thus foetal development may be far advanced. Thus, the incidence of congenital anomaly may be reduced compared to mothers in the first trimester.

### **Visual adverse event of praziquantel**

Several studies have assessed the adverse effect of praziquantel and have reported several events with headache, diarrhea and vomiting been predominant events of praziquantel administration. Recently, there has been concerns of possible adverse effect of praziquantel on vision.

Visual disorders following praziquantel chemotherapy have recently been reported by an Eritrean study, presenting an alarming debate on the safety of the continued use of the drug in treating schistosomiasis. Any such adverse events are not described as the known ‘side effects’ of the use of the drug which chiefly presents with vomiting, dizziness and abdominal discomfort after ingestion. The current review drew on all studies that have reported on the safety of praziquantel, specifically to ascertain the evidence regarding the occurrence of visual disorders after PZQ chemotherapy. None of the five studies included reported serious adverse events requiring hospitalization. In fact, in two of these studies, visual disorders rather occurred in the groups that were not treated with PZQ. Anto et al 2011 recorded eight cases of ‘reddening of the eyes’ in the control area of their study which sought to assess the adverse effects associated with the co-administration of albendazole, praziquantel and ivermectin. In their two-arm comparative study, participants in the control area received only ivermectin and albendazole, and adverse effects were recorded through passive surveillance. Generally, participants that received praziquantel together with the other two drugs had significantly higher reports of headache and general body weakness but all such cases were mild and did not require hospitalization. Existing studies does not support the evidence of praziquantel having an adverse visual effect.

### **Comparison of side effects between SAC and adults**

Over the years, there have been several concerns about the dilapidating effect of *Schistosoma* on the growth and development of infected children. As such the WHO in 2010 recommended the administration of praziquantel in children particularly pre-school attending children (Coulibaly 2007). This is to help reduce the burden of schistosomiasis on the children. Since schistosomiasis in children has been associated with anaemia (Friedman et al 2005) impaired growth and impaired cognitive function (Nampijja et al 2012; Ezeamam et al 2005).

From the meta-analysis, it is observed that for most of the side effects witnessed, the risk of experiencing an adverse event was high in the school attending children compared to the adults. Several studies such as Stelma et al 1995; Berhe et al 1999 have attributed the increased risk of side effect and its intensity to the pre-treatment Schistosoma egg load. From these studies, it was concluded that increased Schistosoma egg load was associated with an increased intensity of side effects. Additionally, several studies have established that in the Schistosoma egg load is increased in school attending children compared to adults. Thus, This increased risk of side effect in School attending children is due to the viral load. since the incidence of side effect largely depends on the drug concentration of praziquantel in blood, an age-related model by Bonate et al 2018 reveals that since the metabolism of praziquantel depends on the CYP activity, the drug remains in circulation longer, resulting in a higher AUC in children due to decreased CYP activity. Thus, the increased likelihood of experiencing side effects in children compared to an adult.

### **Authors Conclusions**

Praziquantel showed to be safe as frequently reported adverse events were mild-to-moderate and transient, and although there were some severe events, these resolved without further intervention. Only few studies reported serious adverse events but these raise concerns. Given that adverse events studies have assessed incidence of events within a very short window, intermediate to long term events would have been missed with serious public health implications. Although the evidence is inconclusive, the fact that some of the few studies that assessed safety in pregnant women reported some serious events, calls for caution in the inclusion of pregnant women in preventive chemotherapy campaigns. The results from studies suggesting that Praziquantel is associated with serious visual adverse events raise concerns but the evidence is inconclusive. This systematic review has exposed the lack of methodological rigour in adverse events studies and recommends that future research should incorporate robust designs, methods, conduct and reporting, using quality-assured tools and following best practices. Further research is needed to obtain and collate topic-specific empirical evidence in the following areas: tissue organ damage and blood chemistry analysis to provide evidence on long term safety of Praziquantel, as well safety in pregnant women and their foetuses. Other areas that need further evaluation are Praziquantel use in those with co-morbidity and on polypharmacy, mixed schistosome infections and schistosome co-infection with other diseases such as taeniasis,

filariasis and trachoma, as well as co-administration with drugs used in other preventive chemotherapy programmes.

## References

- 1 Adam, I., Elwasila, E. T. and Homeida, M. (2004) Is praziquantel therapy safe during pregnancy? *Transactions of the Royal Society of Tropical Medicine and Hygiene* 98: 540-543.
- 2 Adam, I., Elwasila, E. and Homeida, M. (2005) Praziquantel for the treatment of schistosomiasis mansoni during pregnancy. *Annals of Tropical Medicine and Parasitology* 99(1): 37-40.
- 3 Adoubryn K.D., Kouadio-Yapo C.G., Ouhon J., Aka N.A.D., Bintto F., Assoumou A. Intestinal parasites in children in Biankouma, Ivory Coast (mountainous western region): efficacy and safety of praziquantel and albendazole. *Médecine et Santé Tropicales* 2012; 22: 170-176.
- 4 Ahmed THE, Ali AA, Bassiouni GA, Omer SH and Shalaby MA (1988) Praziquantel in treatment of *S.mansoni* and *S.haematobium* infections. *Journal of the Egyptian Society of Parasitology*. 18(1)
- 5 Al-Aska AK, Al-Mofleh IA, Al-Rashed R, Hafez MA, Al-Nozha M, Abu-Aisha H, Al-Balla SR and Taha A. Praziquantel, Oxamniquine and Metrifonate in the treatment of Schistosomiasis in Riyadh. *Annals of Saudi Medicine*. 1990; 10(3):296-298
- 6 Alonso-Coello P, Schunemann HJ, Moher J, et al. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction. *BMJ* 2016; **353**: i2016.
- 7 Amin MA, Swar M, Kardaman M, Elhoussein D, Nouman G, Mahmoud A, Danso-Appiah A, Babiker A, Homeida M. Treatment of pre-school children under 6 years of age for schistosomiasis: safety, efficacy and acceptability of praziquantel. *Sudan Journal of Medical Sciences*. 2012; 7(2):67-79.
- 8 Anto F, Asoala V, Anyorigiya T, Oduro A, Adjuik M, Akweongo P, Aborigo R, Bimi L, Amankwa J, Hodgson A. Simultaneous administration of praziquantel, ivermectin and albendazole, in a community in rural northern Ghana endemic for schistosomiasis, onchocerciasis and lymphatic filariasis. *Tropical Medicine & International Health*, 2011; 16(9), 1112-1119.
- 9 Asfaw, Z., Wolde-Michael, T., & Wondimagegnehu, T. Assessment of side-effects of praziquantel in a trial treatment of *Schistosoma haematobium* infections in the Afar ethnic group of Ethiopia. *Ethiopian medical journal*, 1988; 26(2), 85-89.
- 10 Ayoub AM, Haider MM, Mamoun M, Gasim IG, Walid NE, Abd AA and Ishag A (2009) Artesunate plus sulfadoxine/pyrimethamine versus praziquantel in the treatment of *Schistosoma mansoni* in eastern Sudan. *Trans. Of the Royal Society of Tropical Medicine and Hygiene*. 32(7)
- 11 Azher, M, Faisal A, El-Kassitni, Wright SG, Mofti A. Exudative Polyserositis and Acute Respiratory Failure Following Praziquantel Therapy. *CHEST*, 1990 (98), 241. Copyright © 1990 by American College of Chest Physician. Downloaded from chestjournal.org Downloaded from on September 4, 2008.
- 12 Bada JL, Trevino B, Cabezos J. Convulsive seizures after treatment with praziquantel. *British Medical Journal*. 1988; (296):646.
- 13 Barda, B., Coulibaly, J. T., Puchkov, M., Huwyler, J., Hattendorf, J., & Keiser, J. Efficacy and safety of moxidectin, synriam, synriam-praziquantel versus praziquantel against *Schistosoma haematobium* and *S. mansoni* infections: a randomized, exploratory phase 2 trial. *PLoS neglected tropical diseases*, 2016; 10(9), e0005008.
- 14 Berhe, N., Gundersen, S. G., Abebe, F., Birrie, H., Medhin, G., & Gemetchu, T. Praziquantel side effects and efficacy related to *Schistosoma mansoni* egg loads and

- morbidity in primary school children in north-east Ethiopia. *Acta tropica*, 1999; 72(1), 53-63.
- 15 Bagheri H, Simiand E, Montastruc J-L, Magnaval J-F. Adverse reactions to anthelmintics. *Annals of Pharmacotherapy*. 2004; 38:383-8.
  - 16 Belizario, V.Y., Amarillo, M.L.E., Martinez, R.M., Mallari, A.O and Tai, C.M.C (2007) Efficacy and safety of 40mg/kg and 60mg/kg single doses of praziquantel in the treatment of schistosomiasis. *Journal of Pediatric Infectious Diseases* 3(2008): 27-34
  - 17 Bonate PL, Wang TL, Passier P, Bagchus W, Burt H, Lupfert C, et al. Extrapolation of praziquantel pharmacokinetics to a pediatric population: a cautionary tale. *J Pharmacokinet Pharmacodyn*. 2018;45(5):747–62. 10.1007/s10928-018-9601-1
  - 18 Bossuyt P. DC, Deeks J., Hyde C., Leeflang M., Scholten R. . Chapter 11: Interpreting results and drawing conclusions. In: Deeks JJ, Bossuyt PM, Gatsonis C (editors), *Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy Version 0.9*. 2013.  
<http://methods.cochrane.org/sdt/sites/methods.cochrane.org.sdt/files/uploads/DTA%20Handbook%20Chapter%2011%20201312.pdf>
  - 19 Branchini ML, Pedro R de J, Dias LC, Deberaldini ER. Double-blind clinical trial comparing praziquantel with oxamniquine in the treatment of patients with schistosomiasis mansoni. *Rev Inst Med Trop Sao Paulo*, 1982;24(5):315-21.
  - 20 Borrmann S, Szlezak N, Faucher J.F, Matsiegui PB, Neubauer R, Binder RK, Lell, B, Kreamsner PG. Artesunate and praziquantel for the treatment of *Schistosoma haematobium* infections: a double-blind, randomized, placebo-controlled study. *Journal of Infectious Diseases*. 2001; 184,1363–1366.
  - 21 Braae, U. C., Magnussen, P., Harrison, W., Ndawi, B., Lekule, F., & Johansen, M. V. (2016). Effect of National Schistosomiasis Control Programme on *Taenia solium* taeniosis and porcine cysticercosis in rural communities of Tanzania. *Parasite epidemiology and control*, 1(3), 245-251.
  - 22 Branchini, M. L. M., Pedro, R. D. J., Dias, L. C., & Deberaldini, E. R. (1982). Double-blind clinical trial comparing praziquantel with oxamniquine in the treatment of patients with schistosomiasis mansoni. *Rev. Inst. Med. Trop. São Paulo*, 24(5), 315-21.
  - 23 Bustinduy, A. L., Kolamunnage-Dona, R., Mirochnick, M. H., Capparelli, E. V., Tallo, V., Acosta, L. P., ... & Hope, W. W. (2020). Population pharmacokinetics of praziquantel in pregnant and lactating Filipino women infected with *Schistosoma japonicum*. *Antimicrobial agents and chemotherapy*, 64(9), e00566-20.
  - 24 Chen, M. G., Fu, S., Hua, X. J., & Wu, H. M. (1983). A retrospective survey on side effects of praziquantel among 25,693 cases of schistosomiasis japonica. *The Southeast Asian journal of tropical medicine and public health*, 14(4), 495-500.
  - 25 Ben-Chetrit, E., Lachish, T., Mørch, K., Atias, D., Maguire, C., & Schwartz, E. (2015). Schistosomiasis in pregnant travelers: a case series. *Journal of Travel Medicine*, 22(2), 94-98
  - 26 Chen, M. G., Fu, S., Hua, X. J., & Wu, H. M. (1983). A retrospective survey on side effects of praziquantel among 25,693 cases of schistosomiasis japonica. *The Southeast Asian journal of tropical medicine and public health*, 14(4), 495-500.
  - 27 Colley DG, Secor WE. Immunology of human schistosomiasis. *Parasite Immunol*. 2014;36(8):347–57.
  - 28 Coulibaly, J. T., Panic, G., Silué, K. D., Kovač, J., Hattendorf, J., & Keiser, J. Efficacy and safety of praziquantel in preschool-aged and school-aged children infected with *Schistosoma mansoni*: a randomised controlled, parallel-group, dose-ranging, phase 2 trial. *The Lancet Global Health*. 2017; 5(7), e688-e698.

- 29 Coulibaly, J. T., N’Gbesso, Y. K., Knopp, S., Keiser, J., N’Goran, E. K., & Utzinger, J. (2012). Efficacy and Safety of Praziquantel in Preschool-Aged Children in an Area Co-Endemic for *Schistosoma mansoni* and *S. haematobium*. *PLoS Neglected Tropical Diseases*, 6(12). <http://doi.org/10.1371/journal.pntd.0001917>.
- 30 Coutinho, A., Domingues, A. L. C., Neves, J., Almeida, S. T. Treatment of Hepatosplenic Schistosomiasis mansoni with Praziquantel. *Arzneim-Forsch./Drug Research*. 1983; 33(1), Nr. 5(1983), pp787-791.
- 31 Creasey AM, Taylor P, and Thomas JEP. Dosage trial of a combination of oxamniquine and praziquantel in the treatment of schistosomiasis in Zimbabwean schoolchildren. *The Central African Journal of Medicine*. 1986; 32(7):165-7.
- 32 da Cunha, A. S., Cancado, J. R., Rezende, G. L. Therapeutical evaluation of different dose regimens of praziquantel in schistosomiasis mansoni, based on the quantitative oogram technique. *Rev. Inst. Med. Trop. Sao Paulo*. 1987; 295:295-304.
- 33 da Cunha, A. S., Pedrosa, R. C. Double-blind evaluation based on the quantitative technique, comparing praziquantel and oxamniquine in human schistosomiasis mansoni. *Rev. Inst. Med. Trop. Sao Paulo*. 1986; 28(5):337-351.
- 34 da Silva, L. C. D., Zeitune, J. M. R., Rosa-Eid, L. M. F., Lima, D. M. C., Antonelli, R. H., Christo, C. H., ... & Carboni, A. D. C. Treatment of patients with schistosomiasis mansoni: a double-blind clinical trial comparing praziquantel with oxamniquine. *Revista do Instituto de Medicina Tropical de São Paulo*. 1986; 28(3), 174-180.
- 35 da Silva, L.C., Sette, H., Christo, C. H., Saez-Alquezar, A., Carneiro, C.R.W., Lacet., C.M., Ohtsuki, N. and Raia, S. Praziquantel in the treatment of the hepatosplenic form of *Schistosomiasis mansoni*. *Arzneimittelforschung*. 1981;31(3a):601-3.
- 36 Davis, A., Biles, J. E., Ulrich, A. M. and Dixon, H. (1981). Tolerance and efficacy of praziquantel in phase IIA and II B therapeutic trials in Zambian patients. *Arzneimittelforschung* 31, 568–574.
- 37 De Clercq, D., Vercruyse, J., Kongs, A., Verle’, P.,Dompnier, J. P. and Faye, P. C.(2002). Efficacy of artesunate and praziquantel in *Schistosoma haematobium* infected schoolchildren. *Acta Tropica* 82, 61–66
- 38 de Queiroz, L. C., Drummond, S. C., de Matos, M. L. M., Paiva, M., Batista, T. S., Kansaon, A. Z., & Lambertucci, J. R. (2010). Comparative randomised trial of high and conventional doses of praziquantel in the treatment of schistosomiasis mansoni. *Memórias do Instituto Oswaldo Cruz*, 105(4), 445-448.
- 39 DerSimonian R, Laird N. Meta-analysis in clinical trials revisited. *Contemp Clin Trials* [Internet]. 2015;45:139–45. Available from: <http://dx.doi.org/10.1016/j.cct.2015.09.002>.
- 40 Ejezie, C., & Okeke, G. C. Chemotherapy in the control of urinary schistosomiasis in Nigeria. *The Journal of Tropical Medicine and Hygiene*, 1987; 90(3), 149-151.
- 41 El-Alamy, M. A., Habib, M. A., McNeeley, D. F., & Cline, B. L. (1981). Preliminary results of chemotherapy using praziquantel on a large scale in Qalyub Bilharziasis Project where simultaneous infection with *S. mansoni* and *S. haematobium* exists. *Arzneimittelforschung*, 31, 612-615.
- 42 El-Hawey, A.M., Massoud, A.M., El-Rakieby, A., Rozeik, M.S. and Nassar, M.O. Side effects of praziquantel in bilharzial children on a field level. *Journal of the Egyptian Society of Parasitology*. 1990; 20(2):599-605.
- 43 Elliott, A. M., Kizza, M., Quigley, M. A., Ndibazza, J., Nampijja, M., Muhangi, L., ... & Whitworth, J. A. (2007). The impact of helminths on the response to immunization and on the incidence of infection and disease in childhood in Uganda: design of a randomized, double-blind, placebo-controlled, factorial trial of deworming interventions delivered in pregnancy and early childhood [ISRCTN32849447]. *Clinical trials*, 4(1), 42-57.

- 44 El Masry, N.A., Bassily, S. and Farid, Z (1988). A comparison of the efficacy of various regimens of praziquantel for the treatment of schistosomiasis. *Transactions of the Royal Society of Tropical Medicine and Hygiene*, 82: 719-720
- 45 Erko, B., Degarege, A., Tadesse, K., Mathiwos, A., & Legesse, M. Efficacy and side effects of praziquantel in the treatment of Schistosomiasis mansoni in schoolchildren in Shesha Kekele Elementary School, Wondo Genet, Southern Ethiopia. *Asian Pacific Journal of Tropical Biomedicine*, 2(3), 235–239. [http://doi.org/10.1016/S2221-1691\(12\)60049-5](http://doi.org/10.1016/S2221-1691(12)60049-5).
- 46 Ezeamama AE, Friedman JF, Acosta LP, Bellinger DC, Langdon GC, Manalo DL, Olveda RM, Kurtis JD, Stephen T McGarvey ST. Helminth infection and cognitive impairment among Filipino children. *American Journal of Tropical Medicine and Hygiene*. 2005;72,540–548.
- 47 Farid Z, Woody J, Kamal M. [Praziquantel and acute urban schistosomiasis](#). *Tropical and Geographical Medicine*. 1988;41(2):172.
- 48 Fernandes P and Oliveira CC. Estudo comparative da eficacia do praziquantel, em dois esquemas posologicos, e da oxaminiquina no tratamento da esquistossomose mansonica. *Farmacologica Clinica*. 1985; 93(5-6), 389-393.
- 49 Ferrari, M. L. A., Coelho, P. M. Z., Antunes, C. M. F., Tavares, C. A. P., & Da Cunha, A. S. (2003). Efficacy of oxamniquine and praziquantel in the treatment of Schistosoma mansoni infection: a controlled trial. *Bulletin of the World Health Organization*, 81, 190-196.
- 50 Fletcher M & Teklehaimanot A. *Transactions of the Royal Society of Tropical Medicine and Hygiene*. 1989; 83, 793-797.
- 51 Fonseca CT, Oliveira SC, Alves CC. Eliminating Schistosomes through vaccination: what are the best immune weapons? *Frontiers in Immunology*. 2015;6:95.
- 52 [Frohberg H](#), [Schulze Schencking H](#). Toxicological profile of praziquantel, a new drug against cestode and schistosome infections, as compared to some other schistosomicides. *Arzneimittelforschung*. 1981;31(3a):555-65.
- 53 Fu-Yuan et al., Further experience with Praziquantel in Schistosoma japonicum infection. Report of 716 cases. *Chinese Medical Journal*. 1984; 97(1); 47-52.
- 54 Garba, A., Lamine, M. S., Barkiré, N., Djibo, A., Sofu, B., Gouvras, A. N., ... & Utzinger, J. (2013). Efficacy and safety of two closely spaced doses of praziquantel against Schistosoma haematobium and S. mansoni and re-infection patterns in school-aged children in Niger. *Acta tropica*, 128(2), 334-344.
- 55 Groning, E., Bakathir, H., Salem, A., Albert, L., & Fernández, R. (1985). Effectiveness and tolerance of praziquantel in schistosomiasis. *Revista cubana de medicina tropical*, 37(2), 215-219.
- 56 [Gryseels B, Nkulikyinka I, Coosemans MH. Field trials of praziquantel and oxamniquine for the treatment of schistosomiasis mansoni in Burundi. Transactions of the Royal Society of Tropical Medicine and Hygiene \(1987\) 81, 641-644.](#)
- 57 el Guiniady MA , el Touny MA, Abdel-Bary MA, Abdel-Fatah SA, Metwally A. Clinical and Pharmacokinetic study of praziquantel in Egyptian Schistosomiasis patients with and without liver cell failure. *American Journal of Tropical Medicine and Hygiene*. 1994; 51 (6) 809 – 818.
- 58 Guisse F, Polman K, Stelma FF, Mbaye A, Talla I, Niang M, Deelder MA, Ndir O, Gryseels B. Therapeutic evaluation of Two different dose regimens of praziquantel in a recent Schistosoma mansoni focus in Northern Senegal. *American Journal of Tropical Medicine and Hygiene* 1997; 56(5):511-514.

- 59 Higgins JPT, Savović J, Page MJ, Elbers RG, Sterne JAC. Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). *Cochrane Handbook for Systematic Reviews of Interventions* version 6.2 (updated February 2021). Cochrane, 2021. Available from [www.training.cochrane.org/handbook](http://www.training.cochrane.org/handbook).
- 60 Homeida MMA, Sulaiman SM, Ali HM, Bennet JL. Tolerance of two brands of praziquantel. *The Lancet*. 1989; 391.
- 61 Homeida, M.M.A., El Tom, I.A., Sulaiman, S.M., Daffalla, A.A. and Bennett, J.L. Efficacy and tolerance of praziquantel in patients with *Schistosoma mansoni* infection and Symmers' fibrosis: a field study in the Sudan. [American Journal of Tropical Medicine and Hygiene](#). 1988; 38(3):496-498.
- 62 Yan, D. E. N. G., Ya-lan, Z. H. A. N. G., Su-hua, L. I., Wei-qi, C. H. E. N., Xi-meng, L. I. N., Xi, C. H. E. N., ... & Hong-wei, Z. H. A. N. G. (2018). A KAP survey on taeniasis and cysticercosis in Fangcheng County of Henan Province in 2016. *CHINESE JOURNAL OF PARASITOLOGY AND PARASITIC DISEASES*, 36(3), 19.
- 63 Hoy D, Brooks P, Woolf A, et al. Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. *Journal of Clinical Epidemiology* 2012; 65:934–9.
- 64 Ishizaki, T., Kamo, E., & Boehme, K. (1979). Double-blind studies of tolerance to praziquantel in Japanese patients with *Schistosoma japonicum* infections. *Bulletin of the World Health Organization*, 57(5), 787.
- 65 Jaoko WG, Muchemi G, Oguya FO. Praziquantel side effects during treatment of *Schistosoma mansoni* infected pupils in Kibwezi, Kenya. *East African Medical Journal*. 1996;73(8):499-501.
- 66 Leopold, G., Ungethum, W., Groll, E., Diekmann, H. W., Nowak, H. and Wegner, D. H. (1978). Clinical pharmacology in normal volunteers of praziquantel, a new drug against schistosomes and cestodes. An example of a complex study covering both tolerance and pharmacokinetics. *European Journal of Clinical Pharmacology* 14, 281–291
- 67 Kabatereine, N. B., Tukahebwa, E., Kazibwe, F., Namwangye, H., Zaramba, S., Brooker, S. & Fenwick, A. Progress towards countrywide control of schistosomiasis and soil-transmitted helminthiasis in Uganda. *Transactions of the Royal Society of Tropical Medicine and Hygiene*, 2006; 100(3), 208-215.
- 68 Kabatereine NB, Kemijumbi J, Ouma JH, Sturrock RF, Butterworth AE, Maden H, Ornbjerg N, Dune DW and Vennervald BJ Efficacy and side effects of praziquantel treatment in a highly endemic *Schistosoma mansoni* focus at Lake Albert, Uganda. *Transactions of the Royal Society of Tropical Medicine and Hygiene*. 2003; 97, 599-603.
- 69 Kardaman, M. W., Amin, M. A., Fenwick, A., Cheesmond, A. K., & Dixon, H. G. A field trial using praziquantel (BiltricideR) to treat *Schistosoma mansoni* and *Schistosoma haematobium* infection in Gezira, Sudan. *Annals of Tropical Medicine & Parasitology*, 1983; 77(3), 297-304.
- 70 Kardaman, M. W., Fenwick, A., El Igail, A. B., El Tayeb, M., Daffalla, A. A., & Dixon, H. G. Treatment with praziquantel of schoolchildren with concurrent *Schistosoma mansoni* and *S. haematobium* infections in Gezira, Sudan. *The Journal of tropical medicine and hygiene*, 1985; 88(2), 105-109.
- 71 Katz, N., Rocha, R. S., & Chaves, A (a). Preliminary trials with praziquantel in human infections due to *Schistosoma mansoni*. *Bulletin of the World Health Organization*, 1979;57(5),781-5.
- 72 Katz N (b). Preliminary trials with praziquantel in human infections due to *Schistosoma mansoni*. *Bulletin of the World Health Organization* 1979;57(5):781–5.

- 73 Katz, N., Rocha, R. S., & Chaves, A. Clinical trials with praziquantel in schistosomiasis mansoni. *Revista do Instituto de Medicina Tropical de São Paulo*. 1981; 23(2), 72-78.
- 74 Katz N, Rocha RS. Double-blind clinical trial comparing praziquantel with oxamniquine in *Schistosomiasis mansoni*. *Revista do Instituto de Medicina Tropical de São Paulo*. 1982; 24(5):310-314.
- 75 Katz N, Rocha RS, Lambertucci JR, Greco DB, Pedroso ER, Rocha MO, Flan S. Clinical trial with oxamniquine and praziquantel in the acute and chronic phases of Schistosomiasis mansoni. *Revista do Instituto de Medicina Tropical de São Paulo*. 1983;25(4):173-7.
- 76 Katz N, Rocha RS, Chaves A. Clinical trials with praziquantel in schistosomiasis mansoni. *Revista do Instituto de Medicina Tropical de São Paulo*. 1981;23(2):72-8.
- 77 Keiser, J., Silue JD, K. D., Adiossan, L. K., N'Guessan, N. A., Monsan, N., Utzinger, J., N'Goran, E. K. Praziquantel, Mefloquine-Praziquantel, and Mefloquine-Artesunate-Praziquantel against *Schistosoma haematobium*: A Randomized, Exploratory, Open-Label Trial. *PLoS Neglected Tropical Diseases*, 2014; 8(7).
- 78 Keiser J, N'Guessan NA, Adoubryn KD, Silue KD, Vounatsou P, Hatz C, Utzinger J and N'Goran EK. Efficacy and safety of mefloquine, artesunate, mefloquine-artesunate and praziquantel against *Schistosoma haematobium*: randomized, exploratory open-label trial *Clinical Infectious Diseases*. 2010; 50(9)1205-1213.
- 79 King CH, Sutherland LJ, Bertsch D. Systematic review and meta-analysis of the impact of chemical-based mollusciciding for control of *Schistosoma mansoni* and *S. haematobium* transmission. *PLoS Neglected Tropical Diseases*. 2015; 9(12):e0004290.
- 80 Lo NC, Gurarie D, Yoon N, Coulibaly JT, Bendavid E, Andrews JR, et al. Impact and cost-effectiveness of snail control to achieve disease control targets for schistosomiasis. *Proceedings of the National Academy of Sciences of the United States of America*. 2018; 115(4):E584–E591.
- 81 Leopold, G., Ungethum, W., Groll, E., Diekmann, H.W., Nowak, H. and Wegner, D.H.G Clinical pharmacology in normal volunteers of praziquantel, a new drug against schistosomes and cestodes. *European Journal of Clinical Pharmacology*. 1978; 14, 281-291.
- 82 Massoud, A.A.E., El Kholy, A.M and Anwar, W.A. Assessment of efficacy of praziquantel against schistosoma mansoni infection. *Journal of Tropical Medicine and Hygiene*. 1984; 87, 119-121.
- 83 McMahan JE. A comparative trial of praziquantel, metrifonate and niridazole against *Schistosoma haematobium*. *Annals of Tropical Medicine and Parasitology*. 1983;77(2):139–42.
- 84 McMahan JE. Observations on Praziquantel against *Schistosoma haematobium*. *Arzneimittelforschung*. 1981;31(3a):579-80.
- 85 Niger MDA. Mass drug administration for the control of *S. haematobium* infection in Niger (unpublished data).
- 86 McMahan JE, Kolstrup N. Praziquantel: a new schistosomicide against *Schistosoma haematobium*. *British Medical Journal* 1979;2(6202):1396–8.
- 87 Midzi, N., Sangweme, D., Zinyowera, S., Mappingure, M. P., Brouwer, K. C., Kumar, N. & Mduluza, T. (2008). Efficacy and side effects of praziquantel treatment against *Schistosoma haematobium* infection among primary school children in Zimbabwe. *Transactions of the Royal Society of Tropical Medicine and Hygiene*, 102(8), 759-766.
- 88 Minggang, C., Xiangjin, H., Mingjie, W., Rongji, X., Changbao, Y and Shoubai, J. Dose finding double-blind clinical trial with praziquantel in schistosomiasis japonica patients. *Southeast Asian Journal of Tropical Medicine and Public Health*. 1985;16(2):228-33.

- 89 Mohammed, K. A., Haji, H. J., Gabrielli, A. F., Mubila, L., Biswas, G., Chitsulo, L. & Molyneux, D. H. (2008). Triple co-administration of ivermectin, albendazole and praziquantel in Zanzibar: a safety study. *PLoS Neglected Tropical Diseases*. 2(1), e171.
- 90 Mpairwe, H., Webb, E. L., Muhangi, L., Ndibazza, J., Akishule, D., Nampijja, M. & Elliott, A. M. Anthelmintic treatment during pregnancy is associated with increased risk of infantile eczema: randomised controlled trial results. *Pediatric Allergy and Immunology*, 2011; 22(3), 305-312.
- 91 Muhumuza, S., Olsen, A., Katahoire, A., & Nuwaha, F. (2013). Uptake of Preventive Treatment for Intestinal Schistosomiasis among School Children in Jinja District, Uganda: A Cross Sectional Study. *PLoS ONE*, 8(5). <http://doi.org/10.1371/journal.pone.0063438>.
- 92 Mutapi, F., Rujeni, N., Bourke, C., Mitchell, K., Appleby, L., Nausch, N. & Mduluzza, T. (2011). Schistosoma haematobium treatment in 1–5 year old children: safety and efficacy of the antihelminthic drug praziquantel. *PLoS Neglected Tropical Diseases*. 5(5), e1143.
- 93 Na-Bangchang, K., Kietinun, S., Pawa, K. K., Hanpitakpong, W., Na-Bangchang, C., & Lazdins, J. Assessments of pharmacokinetic drug interactions and tolerability of albendazole, praziquantel and ivermectin combinations. *Transactions of the Royal Society of Tropical Medicine and Hygiene*, 2006; 100(4), 335–345.
- 94 Nalugwa, A., Nuwaha, F., Tukahebwa, E. M., & Olsen, A. Single versus double dose praziquantel comparison on efficacy and *Schistosoma mansoni* re-infection in preschool-age children in Uganda: a randomized controlled trial. *PLoS Neglected Tropical Diseases*. 2015; 9(5), e0003796.
- 95 Namwanje, H., Kabatereine NB and Olsen A (2011) The acceptability and safety of praziquantel alone and in combination with mebendazole in the treatment of *Schistosoma mansoni* and soil-transmitted helminthiasis in children aged 1 – 4 years in Uganda. *Parasitology*. 138, 1586- -1592.
- 96 Namwanje, H., Kabatereine NB and Olsen A (2011) A randomized controlled clinical trial on the safety of co-administration of albendazole, ivermectin and praziquantel in infected schoolchildren in Uganda. *Transactions of the Royal Society of Tropical Medicine and Hygiene*. 105, 181-188.
- 97 Nash, T. E, Hofstetter. M, Cheever, A. W, Ottensen, E. A. (1982). Treatment of *Shistosoma mekongi* with praziquantel: A double-blind study. [American Journal of Tropical Medicine and Hygiene](#). 31(3), 1982, pp972-982
- 98 Ndyomugenyi, R., & Kabatereine, N. Integrated community directed treatment for the control of onchocerciasis, schistosomiasis and intestinal helminths infections in Uganda: advantages and disadvantages. *Tropical Medicine & International Health*. 2003; 8(11), 997-1004.
- 99 N’Goran EK, Gnaka HN, Tanner M and Utzinger J (2003) Efficacy and side-effects of two praziquantel treatments against *Schistosoma haematobium* infection, among schoolchildren from Cote D’Ivoire. *Annals of Tropical Medicine and Parasitology*. 97(1) 37-51
- 100 Njenga, S. M., Ng’Ang’a, P. M., Mwanje, M. T., Bendera, F. S., & Bockarie, M. J. (2014). A school-based cross-sectional survey of adverse events following co-administration of albendazole and praziquantel for preventive chemotherapy against urogenital schistosomiasis and soil-transmitted helminthiasis in Kwale County, Kenya. *PLoS ONE*, 9(2), 6–10.
- 101 Obonyo, C. O., Muok, E. M., & Mwinzi, P. N. Efficacy of artesunate with sulfalene plus pyrimethamine versus praziquantel for treatment of *Schistosoma mansoni* in Kenyan children: an open-label randomised controlled trial. *The Lancet infectious diseases*, 2010; 10(9), 603-611.

- 102 Olds, G. R., King, C., Hewlett, J., Olveda, R., Wu, G., Ouma, J., Peters, P., McGarvey, S., Odhiambo, O., Koech, D., Liu, C. Y., Aligui, G., Gachihi, G., Kombe, Y., Parraga, I., Ramirez, B., Whalen, C., Horton, R. J. and Reeve, P. (1999). Double-blind placebo-controlled study of concurrent administration of albendazole and praziquantel in school children with schistosomiasis and geohelminths. *Journal of Infectious Diseases* 179, 996–1003
- 103 Olliaro, P. L., Vaillant, M. T., Belizario, V. J., Lwambo, N. J., Ould Abdallahi, M., Pieri, O. S., ... & Chitsulo, L. (2011). A multicentre randomized controlled trial of the efficacy and safety of single-dose praziquantel at 40 mg/kg vs. 60 mg/kg for treating intestinal schistosomiasis in the Philippines, Mauritania, Tanzania and Brazil. *PLoS Negl Trop Dis*, 5(6), e1165.
- 104 Olveda RM, Acosta LP, Tallo V, Baltazar PI, Lesiguez JLS, Estanislao GG, Ayaso EB, Monterde DBS, Ida A, Watson N, McDonald EA, Wu HW, Kurtis JD, Friedman JF. 'Efficacy and safety of praziquantel for the treatment of human schistosomiasis during pregnancy: a phase 2, randomised, double-blind, placebo-controlled trial', *Lancet Infectious Disease*. 2016; 16(2), pp. 199–208.
- 105 Omer, AH. Praziquantel in the treatment of mixed *S. haematobium* and *S. mansoni* infections. *Arzneimittelforschung*. 1981; 31, 605–608.
- 106 Oyediran, A. B., Kofie, B. A., Bammeke, A. O. and Bamgboye, E. A. (1981). Clinical experience with praziquantel in the treatment of Nigerian patients infected with *S. haematobium*. *Arzneimittelforschung* 31, 581–584.
- 107 Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. *Bmj*. 2021;372:n160.
- 108 Polderman, A. M., Gryseels, B., Gerold, J. L., Mpamila, K., & Manshande, J. P. (1984). Side effects of praziquantel in the treatment of *Schistosoma mansoni* in Maniema, Zaire. *Transactions of the Royal Society of Tropical Medicine and Hygiene*, 78(6), 752-754.
- 109 Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan—a web and mobile app for systematic reviews. *Systematic reviews*. 2016;5(1):1-10.
- 110 Qian, C., & Gong, F. (2016). Praziquantel for schistosomiasis in pregnancy. *The Lancet Infectious Diseases*, 16(5), 525-526.
- 111 Ramiandrasoa, N. S., Ravoniarimbina, P., Solofoniaina, A. R., Andrianjafy Rakotomanga, I. P., Andrianarisoa, S. H., Molia, S., ... & Rajaonatahina, D. (2020). Impact of a 3-year mass drug administration pilot project for taeniasis control in Madagascar. *PLoS neglected tropical diseases*, 14(9), e0008653.
- 112 Raso, G., N'Goran, E. K., Toty, A., Luginbühl, A., Adjoua, C. A., Tian-Bi, N. T., ... & Utzinger, J. (2004). Efficacy and side effects of praziquantel against *Schistosoma mansoni* in a community of western Côte d'Ivoire. *Transactions of the Royal Society of Tropical Medicine and Hygiene*, 98(1), 18-27.
- 113 Reta, B., & Erko, B. (2013). Efficacy and side effects of praziquantel in the treatment for *Schistosoma mansoni* infection in school children in Senbete Town, northeastern Ethiopia. *Tropical Medicine and International Health*, 18(11), 1338–1343.
- 114 Rezende, G. L. D. Survey on the clinical trial results achieved in Brazil comparing praziquantel and oxamniquine in the treatment of mansoni schistosomiasis. *Revista do Instituto de Medicina Tropical de São Paulo*. 1985; 27(6), 328-336.
- 115 Rugemalila JB, Eyakuze VM. 1981. Use of metrifonate for selective population chemotherapy against urinary schistosomiasis in an endemic area at Mwanza, Tanzania. *East African Medical Journal* 1981;58(1):37–43.

- 116 Santesso N, Glenton C, Dahm P, Garner P, Akl EA, Alper B, Brignardello-Petersen R, Carrasco-Labra A, De Beer H, Hulcrantz M, Kuijpers T, Meerpohl J, Morgan R, Mustafa R, Skoetz N, Sultan S, Wiysonge C, Guyatt G, Schünemann HJ; GRADE Working Group. [GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions](#). *J Clin Epidemiol*. 2020;119:126-135.
- 117 Santos, A. T., Blas, B. L., Nosenas, J. S., Portillo, G. P., Ortega, O. M., Hayashi, M., & Boehme, K. (1979). Preliminary clinical trials with praziquantel in *Schistosoma japonicum* infections in the Philippines. *Bulletin of the World Health Organization*, 57(5), 793.
- 118 Santos, A. T., Blas, B. L., Portillo, G., Nosenas, J. S., Poliquit, O., & Papasin, M. Phase III clinical trials with praziquantel in *S. japonicum* infections in the Philippines. *Arzneimittel-forschung*, 1984; 34(9B), 1221-1223.
- 119 Schutte CH, Osman Y, Van Deventer JM, Mosese G. 1983. Effectiveness of praziquantel against the South African strains of *Schistosoma haematobium* and *S. mansoni*. *South African Medical Journal (Suid-Afrikaanse Tydskrif Vir Geneeskunde)* 1983; 64(1):7-101983;64(1):7-10.
- 120 Sissoko MS, Dabo A, Traore H, Diallo M, Traore B, Konate D, Niare B, Diakite M, Kamate B, Traore A, Bathily A, Tapily A, Traore OB, Cauwenbergh S, Jansen HF and Doumbo OK (2009) Efficacy of artesunate + sulfamethoxypyrazine/pyrimethamine versus praziquantel in the treatment of *Schistosoma haematobium* in children. *PLoS One*. 4(10):e6732 doi:10.1371/journal.pone.0006732.
- 121 Smith M, Clegg JA, Webbe G. 1981. Culture of *Schistosoma haematobium* in vivo and in vitro. *Annals of Tropical Medicine and Parasitology*;70(1):101-7
- 122 Sousa-Figueiredo, J. C., Pleasant, J., Day, M., Betson, M., Rollinson, D., Montresor, A., ... Stothard, J. R. (2010). Treatment of intestinal schistosomiasis in Ugandan preschool children: best diagnosis, treatment efficacy and side-effects, and an extended praziquantel dosing pole. *International Health*, 2(2), 103-113.
- 123 Stelma, F. F., Talla, I., Sow, S., Kongs, A., Niang, M., Polman, K., ... & Gryseels, B. (1995). Efficacy and side effects of praziquantel in an epidemic focus of *Schistosoma mansoni*. *The American journal of tropical medicine and hygiene*, 53(2), 167-170. Sterne JA, Hernan MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. *BMJ* 2016; **355**: i4919.
- 124 Sterne JAC, Hernán MA, McAleenan A, Reeves BC, Higgins JPT. Chapter 25: Assessing risk of bias in a non-randomized study. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). *Cochrane Handbook for Systematic Reviews of Interventions* version 6.2 (updated February 2021). Cochrane, 2021. Available from [www.training.cochrane.org/handbook](http://www.training.cochrane.org/handbook).
- 125 Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson G, Moher D, et al. Meta-analysis of Observational Studies in Epidemiology: A Proposal for Reporting - Meta-analysis Of Observational Studies in Epidemiology (MOOSE) Group B. *JAMA Neurol*. 2000;283:2008-12.
- 126 Sukwa, T. Y. (1993). A community-based randomized trial of praziquantel to control schistosomiasis morbidity in schoolchildren in Zambia. *Annals of Tropical Medicine & Parasitology*, 87(2), 185-194.
- 127 Taddese, K., & Zein, Z. A. (1988). Comparison between the efficacy of oxamniquine and praziquantel in the treatment of *Schistosoma mansoni* infections on a sugar estate in Ethiopia. *Annals of Tropical Medicine & Parasitology*, 82(2), 175-180.
- 128 Tweyongyere R, Mawa PA, Ngom-Wegi S, Ndibazza J, Duong T, Vennervald BJ, Dunne DW, Katunguka-Rwakishaya E, Elliott AM. Effect of praziquantel treatment during

- pregnancy on cytokine responses to schistosome antigens: results of a randomized, placebo-controlled trial. *Journal of Infectious Diseases*. 2008 Dec 15;198(12):1870-9. doi: 10.1086/593215.
- 129 Tweyongyere R, Mawa PA, Kihembo M, Jones FM, Webb EL, Cose S, Dunne DW, Vennervald BJ, Elliott AM. Effect of praziquantel treatment of *Schistosoma mansoni* during pregnancy on immune responses to schistosome antigens among the offspring: results of a randomised, placebo-controlled trial. *BMC Infect Dis*. 2011 Sep 2;11:234. doi: 10.1186/1471-2334-11-234.
- 130 Tweyongyere R, Naniima P, Mawa PA, Jones FM, Webb EL, Cose S, Dunne DW, Elliott AM. Effect of maternal *Schistosoma mansoni* infection and praziquantel treatment during pregnancy on *Schistosoma mansoni* infection and immune responsiveness among offspring at age five years. *PLoS Neglected Tropical Diseases*. 2013 Oct 17;7(10):e2501.
- 131 Watt, G., White, N. J., Padre, L., Ritter, W., Fernando, M. T., Ranoa, C. P., & Laughlin, L. W. (1988). Praziquantel pharmacokinetics and side effects in *Schistosoma japonicum*-infected patients with liver disease. *Journal of Infectious Diseases*, 157(3), 530-535.
- 132 Watt, G. Bloody diarrhea after praziquantel therapy. *Transactions of the Royal Society of Tropical Medicine and Hygiene*. 1986; 80 pp345. Watt G, Adapon B, Long GW, Fernando MT, Ranoa CP, Cross JH. Praziquantel in treatment of cerebral schistosomiasis. *Lancet*. 1986; 6;2(8506):529-32. doi: 10.1016/s0140-6736(86)90110-8.
- 133 Steinmann P, Keiser J, Bos R, Tanner M, Utzinger J. Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. *Lancet Infect Dis*. 2006 Jul;6(7):411-25. doi: 10.1016/S1473-3099(06)70521-7.
- 134 Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, Henry D, Altman DG et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. *British Medical Journal*. 2016;355:i4919. doi: 10.1136/bmj.i4919.
- 135 Sturrock RF. Schistosomiasis epidemiology and control: how did we get here and where should we go? *Mem Inst Oswaldo Cruz*. 2001;96 Suppl:17–27.
- 136 WHO 2012a. Schistosomiasis: Progress Report 2001-2011 and Strategic Plan 2012-2020.
- 137 WHO 2012b. Accelerating work to overcome the global impact of neglected tropical disease: a road map for implementation. WHO/HTM/NTD/2012, 37 pp.
- 138 WHO. Elimination of schistosomiasis. Sixty-fifth World Health Assembly Resolution WHA 65.21. [http://www.who.int/neglected\\_diseases/mediacentre/WHA\\_65.21\\_Eng.pdf](http://www.who.int/neglected_diseases/mediacentre/WHA_65.21_Eng.pdf)
- 139 WHO. Schistosomiasis and soil-transmitted helminthiases: number of people treated in 2020. *Weekly Epidemiological Record*, 2016,9;91(49-50):585-95.
- 140 WHO. Schistosomiasis and soil-transmitted helminthiases: progress report, 2020. *Weekly Epidemiological Record*, No 48, 2021, 96, 585–595
- 141 WHO. WHO guideline on control and elimination of human schistosomiasis. February 2022.
- 142 Hou XY, McManus DP, Gray DJ, Balen J, Luo X-S, He Y-K, Ellis M, Williams GM, Li YS (2008). A randomized, double-blind, placebo-controlled trial of safety and efficacy of combined praziquantel and artemether treatment for acute schistosomiasis japonica in China. *Bulletin of the World Health Organization*, 86(10), 788–95.
- 143 WHO. Ending the neglect to attain the Sustainable Development Goals – A road map for neglected tropical diseases 2021–2030. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IG
- 144 WHO. Preventive chemotherapy data portal. Geneva: World Health Organization; 2021 (<https://www.who.int/data/preventive-chemotherapy>, accessed November 2021).
- 145 WHO. The control of schistosomiasis: Second report of the WHO Expert Committee (WHO technical report series; 912). Geneva: World Health Organization, 2002.


- 146 WHO. Prevention and control of schistosomiasis and soil-transmitted helminthiasis: A Report of WHO Expert Committee. 2006 (WHO Technical Report Series 912) Geneva: World Health Organization, 2006
- 147 WHO. Accelerating work to overcome the global impact of neglected tropical diseases : a roadmap for implementation World Health Organization, 2012.
- 148 WHO. Schistosomiasis: progress report 2001 - 2011, strategic plan 2012 - 2020: World Health Organization, 2013.
- 149 WHO. Safety in administering medicines for neglected tropical diseases. Geneva: World Health Organization; 2021 (<https://www.who.int/publications/i/item/9789240024144>, accessed November 2021).
- 150 WHO. Global health estimates 2016: Disease burden by cause, age, sex, by country and by region, 2000–2016. Geneva: World Health Organization; 2018 ([http://www.who.int/healthinfo/global\\_burden\\_disease/estimates/en/index1.html](http://www.who.int/healthinfo/global_burden_disease/estimates/en/index1.html), accessed November 2021).
- 151 WHO. Global health estimates 2019: Disease burden by cause, age, sex, by country and by region, 2000–2019. Geneva: World Health Organization; 2020 (<https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates>, accessed November 2021).
- 152 WHO. Preventive chemotherapy data portal. Geneva: World Health Organization; 2021 (<https://www.who.int/data/preventive-chemotherapy>, accessed November 2021).
- 153 Wilkins, H. A. and Moore, P. J. (1987). Comparative trials of regimes for the treatment of urinary schistosomiasis in The Gambia. *Journal of Tropical Medicine and Hygiene* 90, 83–92.
- 154 WHO. WHO guideline on control and elimination of human schistosomiasis. 2022, ISBN 978-92-4-004160-8
- 155 Woldemichael T, Wondimagegnehu T. Schistosoma haematobium treatment with praziquantel: preliminary clinical observations. *Ethiop Med J.* 1986 Jul;24(3):155-6.
- 156 Wu, Ming-He, Chen-Ci Wei, Zhao-Yue Xu, Hong-Chang Yuan, Wei-Neng Lian, Qiu-Ji Yang, Min Chen et al. Comparison of the therapeutic efficacy and side effects of a single dose of levo-praziquantel with mixed isomer praziquantel in 278 cases of schistosomiasis japonica. *The American journal of tropical medicine and hygiene*, 45, no. 3 (1991): 345-349.
- 157 Wu, M.H., Wei, C.C., Xu, Z.Y., Yuan, H.C., Lian, W.N., Yang, Q. J., Chen, M., Jiang, Q.W., Wang, C.Z., Zhang, S.J., Liu, Z-D., Wei, R.M., Yuan, S.J., Hu, L.S. and Wu, Z.S. Comparison of the therapeutic efficacy and side effects of a single dose of levo-praziquantel with mixed isomer praziquantel in 278 cases of schistosomiasis japonica. *American journal of tropical medicine and hygiene.* 1991;45(3):345-9.
- 158 von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Lancet* 2007; **370**(9596): 1453-7.

## APPENDIX 1


### SEARCH TERMS

((((((((((((((((((("praziquantel"[MeSH Terms] OR "praziquantel"[All Fields]) OR distocide[All Fields]) OR ("praziquantel"[MeSH Terms] OR "praziquantel"[All Fields] OR "biltricide"[All Fields])) OR pharmamed[All Fields]) AND ("safety"[MeSH Terms] OR "safety"[All Fields])) OR "side effects"[All Fields]) OR "adverse drug reactions"[All Fields]) OR "adverse events"[All Fields]) OR ("toxicity"[Subheading] OR "toxicity"[All Fields])) OR ("immune tolerance"[MeSH Terms] OR ("immune"[All Fields] AND "tolerance"[All Fields]) OR "immune tolerance"[All Fields] OR "tolerance"[All Fields] OR "drug tolerance"[MeSH Terms] OR ("drug"[All Fields] AND "tolerance"[All Fields]) OR "drug tolerance"[All Fields])) OR "safety profile"[All Fields]) OR "side effect"[All Fields]) OR "adverse drug reaction"[All Fields]) OR "adverse event"[All Fields]) AND ("schistosomiasis"[MeSH Terms] OR "schistosomiasis"[All Fields])) OR ("schistosoma"[MeSH Terms] OR "schistosoma"[All Fields]) OR ("schistosoma"[MeSH Terms] OR "schistosoma"[All Fields] OR "schistosome"[All Fields])) OR ("schistosoma"[MeSH Terms] OR "schistosoma"[All Fields] OR "schistosomes"[All Fields])) OR ("schistosoma"[MeSH Terms] OR "schistosoma"[All Fields])) OR mansoni[All Fields]) OR japonicum[All Fields]) OR intercalatum[All Fields]) OR haematobium[All Fields]) OR mekongi[All Fields] AND ("2009/01/01"[PDAT] : "2017/08/31"[PDAT]))


### Study selection flow chart



**Fig 2** The first 30 common adverse events experienced and reported by persons with or without schistosomiasis who received PZQ (arranged in decreasing frequency)



**Fig 3** The second set of adverse events (number 31 to 60 events) arranged in decreasing frequency of events



**Fig 4** The third common adverse events (number 61 to 90 events) in persons with and without schistosomiasis who received PZQ (arranged in decreasing frequency of events)

## Comparing adverse events of PZQ40mg/kg single dose between SAC and Adults




Fig 12 Vomiting




Fig 13 Abdominal pain




Fig 13 Nausea




Fig 14 General discomfort




Fig 15 Fever




Fig 16 diarrhoea




Fig 17 Itching




Fig 18 breathing difficulty




Fig 19 swelling

**Table 5** Comparing PZQ 40 mg/kg with higher doses in RCTs

Study	Country	Schisto type	PZQ dose	Number of Participants	Adverse events	Serious adverse events	Remarks
Olliaro et al 2011a	Brazil	sm	60 x 1	196	Minor adverse events (60 mg/kg dose first): Abdominal pain: 48 vs 47.9% Nausea: 20.4% vs 18.4% Dizziness: 20.4% vs 11.2% Headache: 14.3% vs 12.2% Vomiting: 11.2% vs 5.19% Diarrhoea: 8.2% vs 4.1%	No serious adverse event	Sites differed for transmission and infection intensities (highest in Tanzania and lowest in Mauritania).
			Versus 40 x 1				
Olliaro et al. 2011b	Mauritania	Sm+sh	60 x 1	186	Adverse events were minor and transient with few severe cases. Dizziness, abdominal pain, diarrhoea, vomiting and headache were commonly reported (60 mg/kg dose first): Dizziness: 77.8% vs 9.7% Abdominal pain: 79.6% vs 71.0% Diarrhoea: 41.9% vs 49.5% Vomiting: 10.7% vs 32.3% Headache: 9.7% vs 14.0%	One incidence of serious event was recorded in the higher dose (60 mg/kg). Specific event not reported.	The risk of having at least one AE was higher in the 60 than in the 40 mg/kg group (83% vs. 73% at 4 hours post treatment).
			Versus 40 x 1				
Olliaro et al. 2011c	Philippines	sj	60 x 1	102	Mostly minor adverse events that resolved after few hours but there were some severe events that occurred mostly in the 60 mg/kg arm (60 mg/kg dose first): Mostly mild-to-moderate adverse events with some severe incident cases (60 mg/kg dose first):	No serious event reported	456 patients (54%) had 918 AEs with no difference between arms at 24 hours.
			Versus 40 x 1				
Olliaro et al. 2011d	Tanzania	Sm+Sh	60 x 1	271	Abdominal pain: 88.9% vs 83.8% Diarrhoea: 47.4% vs 49.3% Nausea: 26.7% vs 30.9% Headache: 14.1% vs 9.6% Vomiting: 11.1% vs 16.9% Dizziness: 6.7% vs 9.6% Fever: 0% vs 1.5%.	No serious event reported	The most frequent AE was abdominal pain at both 4hoursh and 24 hours.
			Versus 40 x 1				

**Table 6** Adverse events in mixed infection with *S. mansoni* and *S. haematobium*

Study	Country	Study design	Number of participants	Dose of PZQ (mg/kg)	Adverse events	Serious adverse events	Remarks
Ahmed et al. 1988	Egypt	Not stated		40			
Anto et al. 2011	Ghana	RCT	22448	*	Prevalence of AEs reported as 8.02 per 1000. All AEs were mild, transient and required no hospitalization	None reported	The study did not explicitly report AEs in the 3 participants with coinfection
Coulibaly et al. 2012	Cote D'Ivoire	RCT	234	40	43 children reported adverse events. <b>12/43</b> children had Sm + Sh coinfection. No further information on severity were reported	None reported	But for 4 cases of body and face inflammation classified as moderately severe, all adverse events were mild and resolved on its own
El-Alamy et al. 1981	Egypt	Clinical Trial	353	40	All adverse reactions categorized as mild and self-limiting. Reported signs included fever, rapid pulse and rash. Symptoms included nausea, abdominal pain, dizziness, etc.	None reported	The selected signs and symptoms were present before treatment but increased in frequency post-treatment
Garba et al. 2013	Niger	Clinical Trial	877	40	After 1 <sup>st</sup> dose, 33% of SAC reported AEs within 4 hrs post-treatment; 6.2% reported AEs within 4-24 hrs post-treatment. After 2 <sup>nd</sup> dose, 1.5% of SAC reported AEs within 4hrs post-treatment and none within 4-24hrs AEs were chiefly abdominal pain, sleepiness and headache	None reported	No further information provided on the distribution of AEs. It is unclear how participants with Sh+Sm coinfections were affected
Groning 1985		MDA		40			
Schutte et al. 1983	South Africa	RCT	294	40	AEs were more frequent immediately after treatment compared with 48 hrs post-treatment. There were all mild and required no treatment.	None reported	AEs were more common in participants with Sh+Sm coinfection (Embokodweni) compared with those with only Sh infection (Emophela)
Kardaman et al. 1983	Sudan	RCT	43	40 (20x2)	In the camps (n=81) where there were 43	None reported	There was no significant

					<p>confected participants, abdominal pain (22.2%), vomiting (19.8%), diarrhoea (14.8%), etc. At other sites (Group A and Group B), similar trend of AEs was recorded.</p>		<p>difference in the frequency and severity of AEs observed in the three sites. AEs were described as mild and resolved within 24 hrs</p>
Wilkins 1987a	??		184	40	<p>No serious adverse event. Commonly reported side effects included headache, weakness, dizziness, nausea/vomiting, diarrhoea, abdominal pain, general malaise, and fever. Among these events, abdominal pain, general malaise, and fever were reported more frequently with PZQ treatment</p>	None reported	
Omer et al. 1981	Sudan	RCT	153	40 (20x2)	None reported		<p>All AEs were mild and transient. ECG changes were found to be minimal and unalarming.</p>
El-Masry et al. 1988	Egypt	RCT	204	60 (30x2)	<p>Epigastric pain was the most common AE (up to 66.6% of participants who received 20mg twice daily for 3 days), headache, nausea, vomiting and fever up to 38°C were also common</p>	Not reported	<p>AEs occurred less often in patients treated with 30mg dose and more often in those treated with 120mg</p>

\*height-dosage relationship used where; 94–109 cm = 1 tablet; 110–124 cm = 1½ tablets; 125–137 cm = 2 tablets; 138–149 cm = 2½ tablets; 150–159 cm = 3 tablets; 160–177 cm = 4 tablets and ≥178 cm = 5 tablets

## RISK OF BIAS ASSESSMENT FOR INCLUDED RCT STUDIES

### *Al-Aska et al., 1990*

Bias domain	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Patients were allocated randomly to either PZQ or metrifonate or oxamniquine based on random sequence
Allocation concealment (selection bias)	Low risk	Not reported
Blinding (performance bias and detection bias)	Unclear risk	No information provided
Incomplete outcome data (attrition bias)	Unclear risk	No reporting of attrition
Selective reporting (reporting bias)	Low risk	No indication of selective reporting
Other bias	Low risk	No other bias identified

### *Adoubryn et al., 2012*

Bias domain	Authors' judgement	Support for judgement
Random sequence generation (selection bias)		
Allocation concealment (selection bias)		
Blinding (performance bias and detection bias)		
Incomplete outcome data (attrition bias)		
Selective reporting (reporting bias)		
Other bias		

### *Anto et al., 2011*

Bias domain	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	No random sequence generation described.
Allocation concealment (selection bias)	Unclear risk	No information provided
Blinding (performance bias and detection bias)	Low risk	No blinding but the outcome studied is unlikely to be influenced by lack of blinding.
Incomplete outcome data (attrition bias)	Unclear risk	No report on attrition
Selective reporting (reporting bias)	Unclear risk	No indication of selective reporting
Other bias	Low risk	No other bias identified

### *Ayoub et al., 2009*

Bias domain	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Described as 'randomized' with no further information
Allocation concealment (selection bias)	Unclear risk	No information reported
Blinding (performance bias and detection bias)	Unclear risk	No information reported
Incomplete outcome data (attrition bias)	Unclear risk	No information reported
Selective reporting (reporting bias)	Low risk	No indication of selective reporting

<b>Other bias</b>	Low risk	No other bias identified
-------------------	----------	--------------------------

*Barda et al., 2016*

<b>Bias domain</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
<b>Random sequence generation (selection bias)</b>	Low risk	"...used a computer-generated block randomization code stratified by..."
<b>Allocation concealment (selection bias)</b>	Unclear risk	Subjects were randomly allocated but no further information on concealment
<b>Blinding (performance bias and detection bias)</b>	Low risk	Single blinding. Unlikely it was broken.
<b>Incomplete outcome data (attrition bias)</b>	Unclear risk	Attrition was factored in sample size determination but incomplete data not reported
<b>Selective reporting (reporting bias)</b>	Low risk	No indication of selective bias
<b>Other bias</b>	Low risk	No other bias identified

*Belizario et al., 2008*

<b>Bias domain</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
<b>Random sequence generation (selection bias)</b>	Unclear risk	Participants were randomly assigned with no further details
<b>Allocation concealment (selection bias)</b>	Low risk	Participants were to treatment group
<b>Blinding (performance bias and detection bias)</b>	Low risk	Double blind, unlikely it was broken
<b>Incomplete outcome data (attrition bias)</b>	Unclear risk	No information reported
<b>Selective reporting (reporting bias)</b>	Low risk	No indication of selective bias
<b>Other bias</b>		

*Borrmann et al., 2001*

<b>Bias domain</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
<b>Random sequence generation (selection bias)</b>	Low risk	Computer generated randomization
<b>Allocation concealment (selection bias)</b>	Low risk	Both treatment and placebo drugs identical
<b>Blinding (performance bias and detection bias)</b>	Low risk	Double blind, unlikely it was broken
<b>Incomplete outcome data (attrition bias)</b>	Unclear risk	No information reported
<b>Selective reporting (reporting bias)</b>	Low risk	No indication of selective reporting
<b>Other bias</b>	Low risk	No other risks identified

*Branchini et al., 1982*

<b>Bias domain</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
<b>Random sequence generation (selection bias)</b>	Unclear risk	No information reported
<b>Allocation concealment (selection bias)</b>	Unclear risk	Patients were randomly allocated, no further details reported
<b>Blinding (performance bias and detection bias)</b>	Low risk	Double blind, unlikely it was broken
<b>Incomplete outcome data (attrition bias)</b>	Unclear risk	No information reported
<b>Selective reporting (reporting bias)</b>	Low risk	No indication of selective bias

<b>Other bias</b>		
<i>Coulibaly et al., 2017</i>		
<b>Bias domain</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
<b>Random sequence generation (selection bias)</b>	Low risk	"...using computer-generated stratified block randomisation codes..."
<b>Allocation concealment (selection bias)</b>	Low risk	'Random assignment by computer-generated stratified block randomization codes'
<b>Blinding (performance bias and detection bias)</b>	Low risk	Single blind, unlikely that outcome studied was influenced
<b>Incomplete outcome data (attrition bias)</b>	Low risk	Low attrition, available case analysis
<b>Selective reporting (reporting bias)</b>	Low risk	No indication of selective reporting
<b>Other bias</b>		

<i>Coutinho et al., 1983</i>		
<b>Bias domain</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
<b>Random sequence generation (selection bias)</b>	Unclear risk	No information provided
<b>Allocation concealment (selection bias)</b>	Unclear risk	Patients randomly assigned, no additional details reported
<b>Blinding (performance bias and detection bias)</b>	Unclear risk	No information reported
<b>Incomplete outcome data (attrition bias)</b>	Low risk	All patients' outcome data analysed
<b>Selective reporting (reporting bias)</b>	Low risk	No indication of selective reporting
<b>Other bias</b>	Unclear risk	Seemingly large disparities in patients' clinical presentation which might have affected the outcome

<i>da Cunha et al., 1987</i>		
<b>Bias domain</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
<b>Random sequence generation (selection bias)</b>	Unclear risk	No information reported
<b>Allocation concealment (selection bias)</b>	Unclear risk	Patients were randomly assigned but no further details were reported
<b>Blinding (performance bias and detection bias)</b>	Unclear risk	No information reported
<b>Incomplete outcome data (attrition bias)</b>	Unclear risk	No information reported
<b>Selective reporting (reporting bias)</b>	Low risk	No indication of selective reporting
<b>Other bias</b>	Low risk	No other bias identified

<i>da Cunha et al., 1986</i>		
<b>Bias domain</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
<b>Random sequence generation (selection bias)</b>	Unclear risk	No information reported
<b>Allocation concealment (selection bias)</b>	Unclear risk	Patients were allocated to the two groups based on certain characteristics. No further details were reported regarding concealment
<b>Blinding (performance bias and detection bias)</b>	Low risk	Double blind, unlikely it was tampered

<b>Incomplete outcome data (attrition bias)</b>	Low risk	24 patients out of 27 completed follow-ups
<b>Selective reporting (reporting bias)</b>	Low risk	No indication of selective reporting
<b>Other bias</b>	Low risk	No other bias identified

*da Silva et al., 1986*

<b>Bias domain</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
<b>Random sequence generation (selection bias)</b>	Unclear risk	'patients were randomly assigned into two groups', No information reported
<b>Allocation concealment (selection bias)</b>	Unclear risk	No information reported
<b>Blinding (performance bias and detection bias)</b>	Low risk	Double blind, unlikely it was tampered
<b>Incomplete outcome data (attrition bias)</b>	Unclear risk	No information reported
<b>Selective reporting (reporting bias)</b>	Low risk	No indication of selective reporting
<b>Other bias</b>	Low risk	No other bias identified

*Davis et al., 1981*

<b>Bias domain</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
<b>Random sequence generation (selection bias)</b>	Low risk	Used a table of random numbers.
<b>Allocation concealment (selection bias)</b>	Unclear risk	No information reported
<b>Blinding (performance bias and detection bias)</b>	Low risk	Double blind, unlikely it was broken
<b>Incomplete outcome data (attrition bias)</b>	Unclear risk	No information reported
<b>Selective reporting (reporting bias)</b>	Low risk	No indication of selective reporting
<b>Other bias</b>	Low risk	No other bias identified

*de Queiroz et al., 2010*

<b>Bias domain</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
<b>Random sequence generation (selection bias)</b>	Unclear risk	'subjects were randomly assigned into two groups', no further details reported
<b>Allocation concealment (selection bias)</b>	Unclear risk	No information reported
<b>Blinding (performance bias and detection bias)</b>	Low risk	Single blind, unlikely it influenced the studied outcomes
<b>Incomplete outcome data (attrition bias)</b>	Unclear risk	No information reported
<b>Selective reporting (reporting bias)</b>	Low risk	No indication of selective reporting
<b>Other bias</b>	Low risk	No other bias identified

*El Masry et al., 1988*

<b>Bias domain</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
<b>Random sequence generation (selection bias)</b>	Unclear risk	No information reported
<b>Allocation concealment (selection bias)</b>	Unclear risk	No information reported
<b>Blinding (performance bias and detection bias)</b>	Unclear risk	No information reported

<b>detection bias</b>		
<b>Incomplete outcome data (attrition bias)</b>	Unclear risk	No information reported
<b>Selective reporting (reporting bias)</b>	Unclear risk	No information reported
<b>Other bias</b>	Unclear risk	Short report, certain key information not reported

<b>Fernandez et al., 1985</b>		
<b>Bias domain</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
<b>Random sequence generation (selection bias)</b>		
<b>Allocation concealment (selection bias)</b>		
<b>Blinding (performance bias and detection bias)</b>		
<b>Incomplete outcome data (attrition bias)</b>		
<b>Selective reporting (reporting bias)</b>		
<b>Other bias</b>		

<b>Fu-yuan et al., 1984</b>		
<b>Bias domain</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
<b>Random sequence generation (selection bias)</b>	Unclear risk	No information reported
<b>Allocation concealment (selection bias)</b>	Unclear risk	No information reported
<b>Blinding (performance bias and detection bias)</b>	Low risk	No blinding but unlikely that the outcome was influenced
<b>Incomplete outcome data (attrition bias)</b>	Unclear risk	No information reported
<b>Selective reporting (reporting bias)</b>	Low risk	No indication of selective reporting
<b>Other bias</b>	Low risk	No other bias identified

<b>Gryseels et al., 1987</b>		
<b>Bias domain</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
<b>Random sequence generation (selection bias)</b>	Unclear risk	No information reported
<b>Allocation concealment (selection bias)</b>	Unclear risk	No information reported
<b>Blinding (performance bias and detection bias)</b>	Unclear risk	No information reported
<b>Incomplete outcome data (attrition bias)</b>	Unclear risk	No information reported
<b>Selective reporting (reporting bias)</b>	Low risk	No indication of selective reporting
<b>Other bias</b>	Low risk	No other bias identified

<b>Guiniady et al., 1994</b>		
<b>Bias domain</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
<b>Random sequence generation (selection bias)</b>	Unclear risk	No information reported
<b>Allocation concealment (selection bias)</b>	High risk	Open allocation into groups
<b>Blinding (performance bias and detection bias)</b>	Low risk	No blinding but unlikely that it affected the

<b>detection bias)</b>		outcome
<b>Incomplete outcome data (attrition bias)</b>	Unclear risk	No information reported
<b>Selective reporting (reporting bias)</b>	Low risk	No indication of selective reporting
<b>Other bias</b>	Low risk	No other bias identified

*Guisse et al., 1997*

<b>Bias domain</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
<b>Random sequence generation (selection bias)</b>	Unclear risk	Described 'randomly allocated into two treatment groups'. No further details reported
<b>Allocation concealment (selection bias)</b>	Unclear risk	No information reported
<b>Blinding (performance bias and detection bias)</b>	Unclear risk	No information reported
<b>Incomplete outcome data (attrition bias)</b>	Unclear risk	No information reported
<b>Selective reporting (reporting bias)</b>	Low risk	No indication of selective reporting
<b>Other bias</b>	Low risk	No other bias identified

*Homeida et al., 1989*

<b>Bias domain</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
<b>Random sequence generation (selection bias)</b>	Unclear risk	Described 'randomly allocated to biltricide or distocide tablets' No further details reported
<b>Allocation concealment (selection bias)</b>	Unclear risk	No information reported
<b>Blinding (performance bias and detection bias)</b>	Low risk	Both drugs similar in appearance. Independent assessor blind to treatment administered.
<b>Incomplete outcome data (attrition bias)</b>	Unclear risk	No information reported
<b>Selective reporting (reporting bias)</b>	Low risk	No indication of selective reporting
<b>Other bias</b>	Low risk	No other bias identified

*Ishizaki et al., 1979*

<b>Bias domain</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
<b>Random sequence generation (selection bias)</b>	Unclear risk	No information reported
<b>Allocation concealment (selection bias)</b>	Unclear risk	No information reported
<b>Blinding (performance bias and detection bias)</b>	Unclear risk	No information reported
<b>Incomplete outcome data (attrition bias)</b>	Unclear risk	No information reported
<b>Selective reporting (reporting bias)</b>	Low risk	No indication of selective reporting
<b>Other bias</b>	Unclear risk	Some key information missing which otherwise inform the presence or absence of other bias

*Jaoko et al., 1996*

<b>Bias domain</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
<b>Random sequence generation (selection bias)</b>	Unclear risk	Described as 'random sample of 320 pupils were given PZQ'. No further details reported
<b>Allocation concealment (selection bias)</b>	Unclear risk	No information reported
<b>Blinding (performance bias and</b>	Unclear risk	No information reported

<b>detection bias)</b>		
<b>Incomplete outcome data (attrition bias)</b>	Unclear risk	No information reported
<b>Selective reporting (reporting bias)</b>	Low risk	No indication of selective reporting
<b>Other bias</b>	Low risk	No other bias identified

*Kardman et al., 1983*

<b>Bias domain</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
<b>Random sequence generation (selection bias)</b>	Unclear risk	Described as 'subjects were randomly assigned to one of the two treatment groups' no further details reported
<b>Allocation concealment (selection bias)</b>	High risk	One group described as less cooperative so were the ones treated with single dose
<b>Blinding (performance bias and detection bias)</b>	Unclear risk	No information reported
<b>Incomplete outcome data (attrition bias)</b>	Unclear risk	No information reported
<b>Selective reporting (reporting bias)</b>	Low risk	No indication of selective reporting
<b>Other bias</b>	Low risk	No other bias identified

*Kardaman et al., 1985*

<b>Bias domain</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
<b>Random sequence generation (selection bias)</b>	Unclear risk	Described as 'randomly assigned to group A or B' no further details reported
<b>Allocation concealment (selection bias)</b>	Unclear risk	No information reported
<b>Blinding (performance bias and detection bias)</b>	Unclear risk	No information reported
<b>Incomplete outcome data (attrition bias)</b>	Unclear risk	No information reported
<b>Selective reporting (reporting bias)</b>	Low risk	No indication of selective reporting
<b>Other bias</b>	Low risk	No other bias identified

*Katz et al., 1979*

<b>Bias domain</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
<b>Random sequence generation (selection bias)</b>	Unclear risk	No information reported
<b>Allocation concealment (selection bias)</b>	Unclear risk	No information reported
<b>Blinding (performance bias and detection bias)</b>	Unclear risk	No information reported
<b>Incomplete outcome data (attrition bias)</b>	Unclear risk	No information reported
<b>Selective reporting (reporting bias)</b>	Low risk	No indication of selective reporting
<b>Other bias</b>	Low risk	No other bias identified

*Katz et al., 1981*

<b>Bias domain</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
<b>Random sequence generation (selection bias)</b>	Unclear risk	Described as 'single randomized blind study' no further details reported
<b>Allocation concealment (selection bias)</b>	Unclear risk	No information reported
<b>Blinding (performance bias and detection bias)</b>	Low risk	Single blind, unlikely study outcomes were

<b>detection bias)</b>		influenced
<b>Incomplete outcome data (attrition bias)</b>	Unclear risk	No information reported
<b>Selective reporting (reporting bias)</b>	Low risk	No indication of selective reporting
<b>Other bias</b>	Low risk	No other bias identified

*Katz et al., 1982*

<b>Bias domain</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
<b>Random sequence generation (selection bias)</b>	Unclear risk	Described as 'two parallel groups established by random allocation of patients' no further details reported
<b>Allocation concealment (selection bias)</b>	Unclear risk	No information reported
<b>Blinding (performance bias and detection bias)</b>	Low risk	Double blind, unlikely that outcomes were influenced
<b>Incomplete outcome data (attrition bias)</b>	Unclear risk	No information reported
<b>Selective reporting (reporting bias)</b>	Low risk	No information reported
<b>Other bias</b>	Low risk	No other bias identified

*Katz et al., 1983*

<b>Bias domain</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
<b>Random sequence generation (selection bias)</b>	Unclear risk	No information reported
<b>Allocation concealment (selection bias)</b>	Unclear risk	No information reported
<b>Blinding (performance bias and detection bias)</b>	Unclear risk	No information reported
<b>Incomplete outcome data (attrition bias)</b>	Unclear risk	No information reported
<b>Selective reporting (reporting bias)</b>	Low risk	No indication of selective reporting
<b>Other bias</b>	Unclear risk	Details on some pertinent aspects lacking

*Keiser et al., 2014*

<b>Bias domain</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
<b>Random sequence generation (selection bias)</b>	Low risk	Computer generated randomization codes used
<b>Allocation concealment (selection bias)</b>	High risk	Open-label. Allocation not concealed
<b>Blinding (performance bias and detection bias)</b>	Low risk	No blinding, unlikely that outcomes were influenced
<b>Incomplete outcome data (attrition bias)</b>	Low risk	Available case analysis carried. Attrition low.
<b>Selective reporting (reporting bias)</b>	Low risk	No indication of selection bias
<b>Other bias</b>	Low bias	No other bias identified

*Massoud et al., 1984*

<b>Bias domain</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
<b>Random sequence generation (selection bias)</b>	Unclear risk	No information reported
<b>Allocation concealment (selection bias)</b>	Unclear risk	No information reported
<b>Blinding (performance bias and detection bias)</b>	Unclear risk	No information reported

<b>detection bias)</b>		
<b>Incomplete outcome data (attrition bias)</b>	Unclear risk	No information reported
<b>Selective reporting (reporting bias)</b>	Low risk	No indication of selective reporting
<b>Other bias</b>	Low risk	No other bias identified

*McMahon 1981*

<b>Bias domain</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
<b>Random sequence generation (selection bias)</b>	Unclear risk	No information reported
<b>Allocation concealment (selection bias)</b>	Unclear risk	No information reported
<b>Blinding (performance bias and detection bias)</b>	Unclear risk	No information reported
<b>Incomplete outcome data (attrition bias)</b>	Unclear risk	No information reported
<b>Selective reporting (reporting bias)</b>	Low risk	No indication of selective reporting
<b>Other bias</b>	Unclear risk	Details on some key components of methodology generally lacking

*McMahon & Kolstrup 1979*

<b>Bias domain</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
<b>Random sequence generation (selection bias)</b>	Unclear risk	Described as 'each stratum was randomly subdivided into four groups' no further details reported
<b>Allocation concealment (selection bias)</b>	Unclear risk	No information reported
<b>Blinding (performance bias and detection bias)</b>	Unclear risk	No information reported
<b>Incomplete outcome data (attrition bias))</b>	High risk	Over 30% participants lost to follow-up.
<b>Selective reporting (reporting bias)</b>	Low risk	No indication of selective reporting
<b>Other bias</b>	Low risk	No other bias reported

*McMahon 1983*

<b>Bias domain</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
<b>Random sequence generation (selection bias)</b>	Unclear risk	Described as 'subjects were randomly allocated into treatment groups' no further details reported
<b>Allocation concealment (selection bias)</b>	Unclear risk	No information reported
<b>Blinding (performance bias and detection bias)</b>	Unclear risk	No information reported
<b>Incomplete outcome data (attrition bias))</b>	Unclear risk	No information reported
<b>Selective reporting (reporting bias)</b>	Low risk	No indication of selective reporting
<b>Other bias</b>	Low bias	No other bias identified

*Minggang et al., 1985*

<b>Bias domain</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
<b>Random sequence generation (selection bias)</b>	Low risk	Table of random numbers used in randomizing participants
<b>Allocation concealment (selection bias)</b>	Unclear risk	No information reported

<b>bias)</b>		
<b>Blinding (performance bias and detection bias)</b>	Low risk	Double blind, unlikely that outcomes were influenced
<b>Incomplete outcome data (attrition bias)</b>	Unclear risk	No information reported
<b>Selective reporting (reporting bias)</b>	Low risk	No indication of selective reporting
<b>Other bias</b>	Low risk	No other bias identified
<i>Ming-he et al., 1991</i>		
<b>Bias domain</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
<b>Random sequence generation (selection bias)</b>	Unclear risk	Described as 'randomly distributed into treatment groups' no further details reported
<b>Allocation concealment (selection bias)</b>	Unclear risk	No information reported
<b>Blinding (performance bias and detection bias)</b>	Low risk	Double blind. Unlikely it was broken
<b>Incomplete outcome data (attrition bias)</b>	Unclear risk	No information reported
<b>Selective reporting (reporting bias)</b>	Low risk	No indication of selective reporting
<b>Other bias</b>	Low risk	No other bias identified
<i>Mpairwe et al., 2011</i>		
<b>Bias domain</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
<b>Random sequence generation (selection bias)</b>	Low risk	Random sequence generated by blocks of 100
<b>Allocation concealment (selection bias)</b>	Low risk	Participants allocated to a random sequence
<b>Blinding (performance bias and detection bias)</b>	Low risk	Double blind, unlikely that the blind was broken
<b>Incomplete outcome data (attrition bias)</b>	Low risk	Used Intention to treat analysis
<b>Selective reporting (reporting bias)</b>	Low risk	No indication of selective reporting
<b>Other bias</b>	Low risk	No other risk identified
<i>Na-Bangchang et al., 2005</i>		
<b>Bias domain</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
<b>Random sequence generation (selection bias)</b>	Unclear risk	Described as 'subjects were randomised to receive one of the three study drug regimens' no further details reported
<b>Allocation concealment (selection bias)</b>	Unclear risk	No information reported
<b>Blinding (performance bias and detection bias)</b>	Low risk	Open-label trial, crossover design, unlikely that the outcomes were influenced
<b>Incomplete outcome data (attrition bias)</b>	Unclear risk	no information reported
<b>Selective reporting (reporting bias)</b>	Low risk	No indication of selective reporting
<b>Other bias</b>	Unclear risk	No other bias identified, but the number of participants included were comparatively low
<i>Nalugwa et al., 2015</i>		
<b>Bias domain</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
<b>Random sequence generation (selection bias)</b>	Low risk	Computer random number generation used
<b>Allocation concealment (selection bias)</b>	Low risk	Participants allocated independently randomly

<b>bias)</b>		
<b>Blinding (performance bias and detection bias)</b>	Unclear risk	No information reported
<b>Incomplete outcome data (attrition bias)</b>	High risk	Considerable proportion of participants lost to follow-up
<b>Selective reporting (reporting bias)</b>	Low risk	No indication of selective reporting
<b>Other bias</b>	Low risk	No other bias identified

*Namwanje et al., 2011*

<b>Bias domain</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
<b>Random sequence generation (selection bias)</b>		
<b>Allocation concealment (selection bias)</b>		
<b>Blinding (performance bias and detection bias)</b>		
<b>Incomplete outcome data (attrition bias)</b>		
<b>Selective reporting (reporting bias)</b>		
<b>Other bias</b>		

*Namwanje et al., 2010*

<b>Bias domain</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
<b>Random sequence generation (selection bias)</b>		
<b>Allocation concealment (selection bias)</b>		
<b>Blinding (performance bias and detection bias)</b>		
<b>Incomplete outcome data (attrition bias)</b>		
<b>Selective reporting (reporting bias)</b>		
<b>Other bias</b>		

*Nash et al., 1982*

<b>Bias domain</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
<b>Random sequence generation (selection bias)</b>	High risk	No randomization. 'Patients were grouped' non randomly
<b>Allocation concealment (selection bias)</b>	High risk	Non-concealment of allocation
<b>Blinding (performance bias and detection bias)</b>	Low risk	Double blind, same paper reported an open treatment of a patient
<b>Incomplete outcome data (attrition bias)</b>	Unclear risk	No information reported
<b>Selective reporting (reporting bias)</b>	Low risk	No indication of selective reporting
<b>Other bias</b>	Unclear risk	No other bias identified but study participants comparatively small

*Ndibazza et al., 2010*

<b>Bias domain</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
<b>Random sequence generation (selection bias)</b>	Low risk	'Randomization sequence prepared with blocks of 100'
<b>Allocation concealment (selection bias)</b>	Low risk	'opaque, sealed envelopes numbered with the

<b>bias)</b>		randomization code'
<b>Blinding (performance bias and detection bias)</b>	Low risk	Double blind
<b>Incomplete outcome data (attrition bias)</b>	Low risk	Loss to follow-up relatively minimal
<b>Selective reporting (reporting bias)</b>	Low risk	No indication of selective reporting
<b>Other bias</b>	Low risk	No other bias identified

*Obonyo et al., 2010*

<b>Bias domain</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
<b>Random sequence generation (selection bias)</b>	Low risk	'randomisation sequence was computer generated in blocks of four'
<b>Allocation concealment (selection bias)</b>	Low risk	Study treatment assigned prespecified list of consecutive numbers
<b>Blinding (performance bias and detection bias)</b>	Low risk	Nurses who gave treatment and study participants were unmasked but outcome assessors were masked
<b>Incomplete outcome data (attrition bias)</b>	Low risk	Minimal loss to follow up in both groups but comparable
<b>Selective reporting (reporting bias)</b>	Low risk	No indication of selective reporting
<b>Other bias</b>	Low risk	No other bias identified

*Olds et al., 1999*

<b>Bias domain</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
<b>Random sequence generation (selection bias)</b>	Low risk	'Randomization lists were prepared by WHO/TDR using a randomized block design with a block size of 80.'
<b>Allocation concealment (selection bias)</b>	Low risk	'bottles were identified only with a letter code'
<b>Blinding (performance bias and detection bias)</b>	Low risk	Double blind, 'randomization code was not broken until 6 months post-treatment'
<b>Incomplete outcome data (attrition bias)</b>	Low risk	About 83% participants completed 1 year follow-up
<b>Selective reporting (reporting bias)</b>	Low risk	No indication of selective reporting
<b>Other bias</b>	Low risk	No other bias identified

*Olliaro et al., 2011*

<b>Bias domain</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
<b>Random sequence generation (selection bias)</b>	Low risk	'Computer generated randomization list with blocks of 4'
<b>Allocation concealment (selection bias)</b>	Low risk	'Sealed and numbered envelopes were kept in a locked cabinet'
<b>Blinding (performance bias and detection bias)</b>	Low risk	Outcome assessors blinded to treatment
<b>Incomplete outcome data (attrition bias)</b>	Unclear risk	No information provided
<b>Selective reporting (reporting bias)</b>	Low risk	No indication of selective reporting
<b>Other bias</b>	Low risk	No other bias identified

*Olveda et al., 2016*

<b>Bias domain</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
<b>Random sequence generation</b>	Low risk	'randomly allocated study numbers in blocks of

(selection bias)		six'
Allocation concealment (selection bias)	Unclear risk	No information reported
Blinding (performance bias and detection bias)	Low risk	Double blind
Incomplete outcome data (attrition bias)	Low risk	Minimal loss to follow-up, intention to treat analysis
Selective reporting (reporting bias)	Low risk	No indication of selective reporting. Authors' reported amendment of study sample size
Other bias	Low risk	No other bias identified

*Omer 1981*

Bias domain	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	No information reported
Allocation concealment (selection bias)	Unclear risk	No information reported
Blinding (performance bias and detection bias)	Low risk	Single blind, unlikely that study outcomes were influenced
Incomplete outcome data (attrition bias)	Unclear risk	No information reported
Selective reporting (reporting bias)	Low risk	No indication of selective reporting
Other bias	Low risk	No other bias identified

*Oyediran et al., 1981*

Bias domain	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Random allocation using table of random numbers
Allocation concealment (selection bias)	Unclear risk	No information reported
Blinding (performance bias and detection bias)	Low risk	Double blind
Incomplete outcome data (attrition bias)	Unclear risk	No information reported
Selective reporting (reporting bias)	Low risk	No indication of selective reporting
Other bias	Low risk	No other bias identified, but number of participants differed considerably (for example, 60 in stratum I and 9 in stratum III)

*Rezende 1985*

Bias domain	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Described as 'random allocation of patients' no further details reported
Allocation concealment (selection bias)	Unclear risk	No information provided
Blinding (performance bias and detection bias)	Low risk	Double blind
Incomplete outcome data (attrition bias)	Low risk	Loss to follow-up minimal but in both groups relatively same number of participants did not 'complete the minimum number of three controls'
Selective reporting (reporting bias)	Low risk	No indication of selective reporting
Other bias	Low risk	No other bias identified

*Rugemalila et al., 1984*

Bias domain	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Described as 'randomly allocated by their serial numbers' no further details reported
Allocation concealment (selection bias)	Unclear risk	No information reported
Blinding (performance bias and detection bias)	Low risk	Single blind, unlikely that the study outcomes were influenced
Incomplete outcome data (attrition bias)	Unclear risk	No information reported
Selective reporting (reporting bias)	Low risk	No indication of selective reporting
Other bias	Low risk	No other bias identified

*Santos et al., 1979*

Bias domain	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Described as 'were allocated at random to one of three treatment groups' no further details reported
Allocation concealment (selection bias)	Unclear risk	No information reported
Blinding (performance bias and detection bias)	Low risk	'double blind'
Incomplete outcome data (attrition bias)	Unclear risk	No information reported
Selective reporting (reporting bias)	Low risk	No indication of selective reporting
Other bias	Low risk	No other bias identified

*Santos et al., 1984*

Bias domain	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	No information reported.
Allocation concealment (selection bias)	Unclear risk	No information reported
Blinding (performance bias and detection bias)	Unclear risk	No information reported
Incomplete outcome data (attrition bias)	Unclear risk	No information reported
Selective reporting (reporting bias)	Low bias	No indication of selective reporting
Other bias	Low risk	No other bias identified

*Schutte et al., 1983*

Bias domain	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	No information reported
Allocation concealment (selection bias)	Unclear risk	No information reported
Blinding (performance bias and detection bias)	Unclear risk	No information reported
Incomplete outcome data (attrition bias)	Unclear risk	Authors reported 'extremely high rate of absenteeism' but no further details were reported
Selective reporting (reporting bias)	Low risk	No indication of selective reporting
Other bias	Low risk	No other bias identified but there was high proportion of loss to follow

<i>Sissoko et al., 2009</i>		
Bias domain	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Block randomization used
Allocation concealment (selection bias)	Low risk	Sealed unmarked envelopes used
Blinding (performance bias and detection bias)	Low risk	Double blind, unlikely the blind was broken
Incomplete outcome data (attrition bias)	Low risk	Loss to follow-up relatively low. Intention to treat analysis carried out.
Selective reporting (reporting bias)	Low risk	No indication of selective reporting. Study reporting conforms with scope described in the protocol
Other bias	Low risk	No other bias identified
<i>Smith et al., 1981</i>		
Bias domain	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	No information reported
Allocation concealment (selection bias)	Unclear risk	No information reported
Blinding (performance bias and detection bias)	Unclear risk	No information reported
Incomplete outcome data (attrition bias)	Unclear risk	No information reported
Selective reporting (reporting bias)	Low risk	No indication of selective reporting
Other bias	Unclear risk	Some key methodical details missing
<i>Taddese &amp; Zein 1988</i>		
Bias domain	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Described as 'randomly assigned to four treatment groups' no further details reported
Allocation concealment (selection bias)	Unclear risk	No information reported
Blinding (performance bias and detection bias)	Unclear risk	No information reported
Incomplete outcome data (attrition bias)	Unclear risk	One and five participants lost to follow-up in two groups
Selective reporting (reporting bias)	Low risk	No indication of selective reporting
Other bias	Low risk	No other bias identified
<i>Wilkins &amp; Moore 1987</i>		
Bias domain	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer generated random sets of numbers used in allocation
Allocation concealment (selection bias)	Unclear risk	No information reported
Blinding (performance bias and detection bias)	Low risk	Outcome assessor masked on treatment
Incomplete outcome data (attrition bias)	Low risk	Effects of loss to follow-up on outcomes adequately described
Selective reporting (reporting bias)	Low risk	No indication of selective reporting
Other bias	Low risk	No other bias identified

*Xun-Ya et al., 2008*

Bias domain	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	'computer generated random number list was performed'
Allocation concealment (selection bias)	Low risk	Treatment allocated randomly from generated sequence
Blinding (performance bias and detection bias)	Low risk	Double blind
Incomplete outcome data (attrition bias)	Low risk	Minimal lost to follow-up (9 out of 205)
Selective reporting (reporting bias)	Low risk	No indication of selective reporting
Other bias	Low risk	No other bias identified

Olveda et al. 2016		
<b>Follow up</b>		
<b>Allocation sequence</b>	Low risk	
<b>Allocation concealment</b>	Not Stated	
<b>Blinding</b>	Adequate	
<b>Loss to follow up</b>		

Bustinduy et al. 2020		
<b>Follow up</b>	24 hrs	
<b>Allocation sequence</b>	Not Stated	
<b>Allocation concealment</b>	Not Stated	
<b>Blinding</b>	Not Stated	
<b>Loss to follow up</b>	4.3%	

Webb 2011		
<b>Follow up</b>		
<b>Allocation sequence</b>	Adequate	
<b>Allocation concealment</b>	Adequate	
<b>Blinding</b>	Adequate	
<b>Loss to follow up</b>		
Elliot 2007		
<b>Follow up</b>		
<b>Allocation sequence</b>	Adequate	
<b>Allocation concealment</b>	Not	
<b>Blinding</b>	Adequate	
<b>Loss to follow up</b>	4% lost	

Namara 2017		
<b>Follow up</b>	5years	
<b>Allocation sequence</b>	Not Stated	
<b>Allocation concealment</b>	Not Stated	
<b>Blinding</b>	Not Stated	
<b>Loss to follow up</b>		

### Risk of bias for included cohort studies

Study	Sample source	Exposure assessment	Outcome assessment	Matching	Follow up
Adam 2004	Adequate	Adequate	Adequate	Not matched	Adequate
Adam 2005	Adequate	Adequate	Adequate	Not matched	Adequate
Asfaw, 1988	Not adequate	Adequate	Adequate	Not matched	Adequate
Berhe, 1999	Adequate	Adequate	Adequate	Not matched	No follow-up
da Silva, 1981	Adequate	Adequate	Adequate	Not matched	Adequate
El Hawey 1990	Adequate	Adequate	Adequate	Not matched	Adequate
Erko 2012	Adequate	Adequate	Adequate	Not matched	Adequate
Fletcher 1989	Not adequate	Adequate	Adequate	Not matched	Adequate
Garba, 2013	Adequate	Adequate	Adequate	Not matched	Adequate
Kabatereine 2006	Adequate	Adequate	Adequate	Not matched	
Mamoun 1988	Adequate	adequate	adequate	Not matched	
Midizi 2008	Adequate	Adequate	Adequate	Not matched	Adequate
minggang 1983	Not adequate	Adequate	Adequate	Not matched	
Mohammed 2008	Adequate	Adequate	Adequate	Not matched	Adequate
Mutapi 2011	Adequate	Adequate	Adequate	Not matched	Adequate
Ndyomugenyi 2003	Not adequate	Adequate	Adequate	Not matched	No follow-up
Polderman 1984	Not adequate	Adequate	Adequate	Not matched	Adequate
Tweyonyere 2009	Adequate	Adequate	adequate	Not matched	Adequate
Raso et al., 2004	Adequate	Adequate	Adequate	Matched	Adequate
Reta et al 2013	Adequate	Adequate	Adequate	Matched	Adequate
Sousa-Figueiredo 2010	Adequate	Adequate	Adequate	Not matched	Adequate
Watt 1986	Not adequate	Adequate	Adequate	Not matched	Adequate
Watt 1988	Adequate	Adequate	Adequate	Not matched	Adequate
Leopold 1978	Not adequate	Adequate	Adequate	Not matched	Adequate